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Résumé 
 
 Deux tiers des cancers du sein expriment des récepteurs hormonaux ostrogéniques 
(tumeur ER-positive) et la croissance de ces tumeurs est stimulée par l’estrogène. Des 
traitements adjuvant avec des anti-estrogènes, tel que le Tamoxifen et les Inhibiteurs de 
l’Aromatase peuvent améliorer la survie des patientes atteinte de cancer du sein. Toutefois la 
thérapie hormonale n’est pas efficace dans toutes les tumeurs mammaires ER-positives. Les 
tumeurs peuvent présenter avec une résistance intrinsèque ou acquise au Tamoxifen.  
Présentement, c’est impossible de prédire quelle patiente va bénéficier ou non du Tamoxifen. 
 Des études préliminaires du laboratoire de Dr. Mader, ont identifié le niveau 
d’expression de 20 gènes, qui peuvent prédire la réponse thérapeutique au Tamoxifen (survie 
sans récidive). Ces marqueurs, identifié en utilisant une analyse bioinformatique de bases de 
données publiques de profils d’expression des gènes, sont capables de discriminer quelles 
patientes vont mieux répondre au Tamoxifen.  
 Le but principal de cette étude est de développer un outil de PCR qui peut évaluer le 
niveau d’expression de ces 20 gènes prédictif et de tester cette signature de 20 gènes dans une 
étude rétrospective, en utilisant des tumeurs de cancer du sein en bloc de paraffine, de patients 
avec une histoire médicale connue. Cet outil aurait donc un impact direct dans la pratique 
clinique. Des traitements futiles pourraient être éviter et l’indentification de tumeurs ER+ avec 
peu de chance de répondre à un traitement anti-estrogène amélioré. En conséquence, de la 
recherche plus appropriée pour les tumeurs résistantes au Tamoxifen, pourront se faire. 
Mots-clés : Récepteurs hormonaux, Cancer invasif du sein, Récepteurs ostrogénique, Facteur 
prédictif, Profil d’expression, PCR, outil prédictif 
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Abstract 
 
 Two thirds of breast cancers express the estrogen receptor (ER-positive tumours) and 
estrogens stimulate growth of these tumours. Adjuvant therapy with anti-estrogens such as 
Tamoxifen and Aromatase Inhibitors has been shown to increase survival in breast cancer 
patients. This treatment is, however, not successful in all ER-positive tumours. Tumours can 
present intrinsic or acquired resistance to Tamoxifen. However, it is currently impossible to 
predict which patient will benefit from Tamoxifen therapy and which will not. 
 Preliminary studies in Dr. Mader’s lab have identified 20 genes whose expression levels 
in tumours are able to predict the response to Tamoxifen therapy (disease-free survival).  
These markers, identified using bioinformatics analysis of published gene expression datasets, 
were able to discriminate patients that would respond best to Tamoxifen from those that did 
not. 
 The overall purpose of this study is to develop a PCR kit to monitor expression levels of 
these 20 genes and to test this 20-gene signature in a retrospective study using paraffin-
embedded breast cancer tissues of patients with a known medical history. This tool may thus 
have a direct impact on clinical practice through the development of markers of therapeutic 
success for treatment with Tamoxifen and possibly Aromatase Inhibitors. Futile treatments 
would be avoided thus preventing needless side effects, and improved identification of ER+ 
tumours with a low chance of success to anti-estrogen therapy. This will facilitate research 
into more appropriate treatments for hormone resistant tumours. 
Keywords : Hormone receptors, Invasive breast cancer, Estrogen receptor, predictive factor, 
expression profile, PCR, predictive tool 
 iii
Table of Contents 
Introductory Pages 
 Résumé…………………………………………………………………i 
 Mots clés……………………………………………………………….i 
 Abstract..……………………………………………………………….ii 
 Keywords.……………………………………………………………...ii 
 Table of Contents……………………………………………………...iii-vi 
 List of Tables…………………………………………………………..vii 
 List of Figures………………………………………………………….viii 
 List of Abbreviations…………………………………………………...ix-x 
 Dedication……………………………………………………………....xi 
 Acknowledgements……………………………………………………..xii 
 
SECTION 1.   INTRODUCTION 
1.1 Epidemiology……………………………………………………………..1 
1.2 Risk Factors……………………………………………………………….2-9 
Gender and age 
Race and Ethnicity 
Benign Breast Lesions 
Personal History of Breast Cancer 
Family History and Genetic Factors 
Reproductive and Hormonal Factors 
Pregnancy Related Factors 
Exogeneous Hormone Factors 
Ionizing Radiation 
Lifestyle and Dietary Factors 
Alcohol Intake 
 
1.3 Molecular Subtypes of Breast Cancer……………………………………9-12 
Luminal Subtype 
Her-2 enriched Subtype 
Basal-like Subtype 
Claudin-low Subtype 
Normal-like Subtype 
 
 iv
1.4 ER/PR positive breast cancer…………………………………………..12-15 
Molecular biology and physiology of the estrogen receptor 
Estrogen and the mammary gland 
 
1.5 Hormone Therapy for ER/PR positive breast cancer…………………...15-20 
Tamoxifen 
Aromatase Inhibitors 
Fulvestrant 
Efficacy of Hormone Treatment 
  
1.6 Resistance to Tamoxifen………………………………………………..20-25 
Intrinsic Resistance 
 Loss of ER- α expression/function 
 Altered Expression ER-β 
 Tissue-specific availability of co-activators and co-repressors 
 Modulation of ER expression through secondary messengers 
 Modulation of ER- α expression by BRCA1 
 Altered Tamoxifen Metabolism 
Acquired Resistance 
 Loss of ER-α expression/function 
 Co-repressors and co-activators expression levels 
 Growth factor pathways 
 
1.7 DNA Microarray versus RT-QPCR…………………………………….25-28 
DNA Microarray 
RT-QPCR 
 
1.8 Predictive versus Prognostic tools in Breast Cancer……………………28-30 
 
1.9 Predictive Tools in Breast Cancer……………………………………….31 
 
1.10 Development of gene signature predicting the response to Tamoxifen..31-34 
1.11 Identified Predictive Genes ……………………………………………34-43 
Good Predictors 
Poor Predictors 
 
 
SECTION 2.  HYPOTHESIS AND OBJECTIVES 
2.1 Hypothesis………………………………………………………………44 
2.2 Objectives……………………………………………………………….44-45 
 
 v
SECTION 3.  MATERIALS AND METHODS 
3.1 Gene Selection…………………………………………………………..46-48 
3.2 Cell Line Selection………………………………………………………49 
3.3 RNA extraction………………………………………………………….50-53 
 Cell Lines 
 Fresh Tissue 
 Formalin-fixed Paraffin Embedded Tissue 
 
3.4 Quality Assessment of RNA…………………………………………….53-55 
 NanoDrop 
 Agilent BioAnalyzer 
 
3.5 Reverse Transcription…………………………………………………….55 
 Cell Lines 
 Fresh Tissue and Formalin-fixed Paraffin Embedded Tissue 
 
3.6 Q-PCR Probe Selection…………………………………………………56-57 
3.7 Q-PCR…………………………………………………………………..58 
3.8 Selection of Housekeeping genes……………………………………….58-59 
3.9 Creation of a Low Density Array……………………………………….59 
 
SECTION 4.  RESULTS 
4.1 Selection of Housekeeping genes……………………………………….60-64 
  
4.2 Selection of Predictive genes……………………………………………64-68 
 
4.3 Assessment of expression levels in fresh tissue and FFPE samples…….69-80 
  
4.4 Final selection of the gene signature…………………………………….81-82 
 
SECTION 5.  DISCUSSION AND CONCLUSION 
 5.1 Reproducibility between Q-PCR assays and microarray results………....83 
 5.2 Reproducibility of expression profiles between fresh and FFPE samples83-85 
 5.3 Tumour clustering based on gene signature expression patterns………...85 
 vi
 5.4 Rationale for an LDA platform for this tool…………………………….85-86 
  
5.5 Predictive tools in Breast Cancer………………………………………..86-90 
 Oncotype Dx 
 Mammaprint 
 Other Genomic tools 
 
 5.6 Clinical Utility of our tool………………………………………………90-91 
 5.7 Limitations……………………………………………………………....92 
 5.8 Future Perspectives……………………………………………………...92-94 
 Patient Section and History 
 Creation of Recurrence Score 
 
SECTION 6.  REFERENCES…………………………………..95-105 
 
SECTION 7.  APPENDICES……………………………………i-xxvi 
 
Appendix A:  Isolation of RNA using Trizol Reagent 
Appendix B:  ABI Protocol – RNA Extraction from Fresh tissue 
Appendix C:  RNA Isolation from Fresh Tissue using QIAzol 
Appendix D:  RNA Isolation from FFPE – ABI Protocol 
           RecoverAll Total Nucleic Acid Isolation 
Appendix E:  RNA Isolation from FFPE – Roche Protocol 
           High Pure RNA Paraffin Kit 
Appendix F:  RT-PCR used for cell lines 
Appendix G:  RT-PCR used for Fresh and FFPE tissue 
           High Capacity cDNA RT Kit (ABI) 
Appendix H:  Q-PCR ABI Protocol 
Appendix I:  Analysis of Results from Q-PCR 
Appendix J:  Q-PCR on LDA Protocol 
Appendix K:  Consent Form and Research Protocol 
Appendix L:  Approval of Scientific Committee 
Appendix M:  Approval of Ethics Committee 
 vii
List of Tables 
 
Table I: Germ Line Mutations in Breast Cancer 
 
Table II: Genes that predict a good response to Tamoxifen 
 
Table III: Genes that predict a poor response to Tamoxifen 
 
Table IV: Identified Predictive Genes 
 
Table V: Cell lines and culture medium 
 
Table VI: Difference between Roche and ABI Protocol for RNA extraction from 
FFPE tissues 
 
Table VII: TaqMan Assays used for the Q-PCR experiments 
 
Table VIII: Quantity and Quality of RNA extraction from Cell Lines (N1, N2) 
 
Table IX: Housekeeping genes 
 
Table X: Quantity and Quality of RNA extraction from Fresh Tissue (ABI vs. 
CHUM QIAzol Protocol) 
 
Table XI: Quantity and Quality of RNA extraction from FFPE (ABI Protocol 
before and after RNA clean-up) 
 
Table XII: Quantity and Quality of RNA extraction from FFPE (Adapted ABI 
Protocol) 
 
Table XIII: Quantity and Quality of RNA extraction from FFPE (ABI vs. Roche 
Protocol) 
 
Table XIV: Quantity and Quality of RNA extraction from FFPE and Fresh 
Tissue of the same tumour 
 
Table XV: The Final 24 genes on the LDA card  
 viii
List of Figures 
 
Figure 1: Incidence rate of breast cancer by age and race for 2000-2003. 
 
Figure 2: The different modes of action of ER (Genomic and Non-genomic) 
 
Figure 3: Prognostic versus Predictive tools  
 
Figure 4: Heat map of the 30-gene signature applied to several published data 
sets demonstrating its ability to predict the response to Tamoxifen 
 
Figure 5: GeNorm Results (N1) 
 
Figure 6: GeNorm Results (N2) 
 
Figure 7: Heatmap results of the 30 Predictive genes in the 8 cell lines (N1) 
 
Figure 8: Heatmap results of the 30 Predictive genes in the 8 cell lines (N2) 
 
Figure 9: Correlation between ABI QPCR and Affymetrix Micro-Array of the 
30 predictive genes on the 8 cell lines (N1 + N2) 
 
Figure 10: Heatmap results of 24 Predictive genes in 8 different tumour samples 
where RNA was extracted from FFPE tissues 
 
Figure 11: The distribution of the average CT between fresh and paired FFPE 
tumours. (A) Biological replicate 1 and (B) Biological replicate 2. 
 
Figure 12: Heatmap correlation of the 25 predictive genes between Fresh and 
paired FFPE tumour samples. 
 
Figure 13: Pearson correlation between paired Fresh and FFPE tissues (N1 and 
N2) 
 ix
List of Abbreviations 
 
ABI – Applied Biosystems Inc. 
AF – Activating Functions 
AI – Aromatase Inhibitor 
BMI – Body Mass Index 
BRCA1 – Breast Cancer Susceptibility gene 1 
BRCA2 - Breast Cancer Susceptibility gene 2 
cDNA – Complimentary DNA 
CHUM – Centre Hospitalier de l’Université de Montréal 
CSR – Core Serum Response 
CYP2D6 - Cytochrome P450 2D6 
DNA - Deoxyribonucleic acid 
EBCTCG – Early Breast Cancer Trialists Collaborative Group 
EGFR – Epidermal Growth Factor Receptor 
EMT – Epithelial-Mesenchymal Transition 
ER – Estrogen Receptor 
ER+ - Estrogen Receptor Positive 
ER- - Estrogen Receptor Negative 
ER-α – Estrogen Receptor Alpha 
ER-β – Estrogen Receptor Beta 
ERBB2 - Erythroblastic leukemia viral oncogene homolog 2 
ERE – Estrogen response elements 
ESR1 – Estrogen Receptor 1 
FFPE – Formalin-fixed paraffin embedded  
HER-2 - Human Epidermal Growth Factor Receptor 2 
 x
HR – Hazard Ratio 
IRIC – Institut de Recherche d’Immunologie et de Cancérologie 
LDA – Low density array 
mRNA – Messenger RNA 
NSABP – National Surgical Adjuvant Breast and Bowel Project 
PR – Progesterone Receptor 
PR+ - Progesterone Receptor Positive 
PR- - Progesterone Receptor Negative 
Q-PCR – Quantitative Polymerase chain reaction 
RIN – RNA Integrity Number 
RNA - Ribonucleic acid 
RR – Relative Risk 
RS – Recurrence Score 
RT – Reverse Transcription 
RT-PCR – Reverse Transcription Polymerase chain reaction 
SERM – Selective Estrogen Receptor Modulator 
SERD – Selective Estrogen Receptor Downregulator 
TNBC – Triple Negative Breast Cancer 
UV - Ultraviolet 
 
 
 xi
 
 
I would like to dedicate this paper to my husband Matt, and my family for their support 
 
 xii
 Acknowledgments 
I would like to thank my supervisor Sylvie Mader for her guidance and teachings. I 
would also like to thank my supervisor André Robidoux for his support and helping me 
initiate this project. I would like to acknowledge Slim Fourati for his significant contribution 
and help with this project, without whom this project would have not been possible.  I would 
also like to thank the following members of the lab of Sylvie Mader for their support and 
teachings: Martine Bail, Edlie St-Hilaire, Maxime Parisotto, David Cotnoir-White, Laurence 
Fleury, Virginie Dupont and Marieke Rozendaal. 
1. Introduction 
1.1 Epidemiology 
 In Canada, one out of nine women will be diagnosed with breast cancer in their 
lifetime, by age 901. Breast Cancer is the most common cancer in women and the second most 
common cause of cancer death in women. It is the main cause of death in women aged 40-59. 
Fifty percent of the cases can be explained by risk factors and 10% are found to have a 
positive family history. Only 5% of all breast cancers have known genetic mutations and 
syndromes such as BRCA1 and BRCA2. The majority of breast cancers are thus considered 
sporadic cancers2. 
 In 2010, an estimated 23 200 women and 180 men in Canada were diagnosed with 
breast cancer. Approximately 445 Canadian women are diagnosed with breast cancer every 
week. In 2010, an estimated 5300 women and 50 men died of breast cancer in Canada.  This 
means that, on average 100 women die of breast cancer in Canada, every week1. 
 Globally, breast cancer incidence rates are highest in North America and Northern 
Europe and lowest in Asia and Africa. The incidence in China and Japan has been rising in 
recent years3. 
 Since 1999, the incidence of breast cancer has remained quite stable, however, since 
1986 the death rate from breast cancer has declined by more than 30%. This improvement in 
survival rate is most likely due to improvements in treatment strategies as well as better 
screening for breast cancer1. The decrease in mortality has been especially noted in women 
younger than 503 and women with ER/PR positive tumours4. At present, the five-year relative 
survival rate for female breast cancer is 87% (84% for men)1. 
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1.2 Risk Factors 
There are many risk factors that have been found to be associated with breast cancer. 
Some risk factors are stronger than others.   
Gender and Age 
Gender and age are among the strongest risk factors for breast cancer. Women are 
afflicted with breast cancer 100 times more frequently than men. In general, the older the 
person, the higher the risk. The incidence rises sharply with age until about the age of 45-50 
and then the rise becomes less steep. At age 75-80, the incidence curve flattens and slightly 
decreases, as most women at this stage are menopausal and thus have less estrogen stimulation 
(Figure 1, p. 2)5. 
Age-specific SEER incidence, rates of female breast cancer per 100,000, 2000-2003 
 
Figure 1: Incidence rate of breast cancer by age and race for 2000-2003 
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Race and Ethnicity 
Breast cancer is more common in whites and less common in Hispanic and African 
American women. However, African American women tend to have more aggressive, 
hormone receptor negative cancers at a younger age and thus a lower survival rate3. 
Benign breast lesions 
Proliferative benign diseases with cytological atypia increase the risk for breast cancer. 
Atypical lobular hyperplasia or atypical ductal hyperplasia, have a 4-6 fold relative risk (RR) 
of developing breast cancer and this becomes a 10-fold risk when the atypia is multifocal6. 
Personal History of Breast Cancer 
A personal history of invasive breast cancer or a ductal carcinoma in situ also increases 
a person’s risk of having a cancer in the contralateral breast. With in situ lesions, the 10-year 
risk of developing an invasive cancer in the contralateral breast is 5%. In patients that have 
already had an invasive cancer the risk of developing a contralateral breast cancer is 1% in 
premenopausal women and 0.5% in postmenopausal women7. 
Family history and genetic risk factors 
A positive family history is an important risk factor, however, it is only reported by 15-
20% of women diagnosed with breast cancer. In a pooled analysis done in 2001 by the 
Collaborative Group on Hormonal Factors in Breast Cancer, data was used from over 50 000 
women with breast cancer and 100 000 controls. The results showed that the risk of breast 
cancer for a woman with one affected first-degree relative was increased 1.80 fold. With two 
affected first-degree relatives, the risk is increased 2.93 fold. The risk ratios were highest for 
women with young affected relatives. Thus, the risk was increased 2.9 fold for a woman 
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whose relative was diagnosed before age 30, but only 1.5 fold increased if the affected relative 
was diagnosed after age 60. Similarly, if one relative had breast cancer before age 40, the risk 
of breast cancer was increased 5.7-fold8. 
Specific genetic mutations that predispose to breast cancer are very rare; only 5 to 6% 
of all breast cancers are directly attributable to inheritance of a breast cancer susceptibility 
gene (Table I, p. 5). Genetic mutations in these genes are often associated with various cancer 
syndromes, where patients may be afflicted with more than one type of cancer and various 
diseases. These germ-line mutations, which are often associated with triple-negative breast 
cancer (TNBC), are beyond the scope of this thesis, which focuses on the prognostic role of 
somatic mutations.  
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Table I: Germ Line Mutations in Breast Cancer 
Mutation Associated Cancers/Diseases 
BRCA1 
 Breast Cancer 
 Ovarian Cancer (higher risk than BRCA2) 
 Cervical Cancer 
 Uterine Cancer 
 Pancreatic Cancer 
 Colon Cancer 
 Male Breast Cancer (lower risk than BRCA2) 
 Testicular Cancer 
 Prostate Cancer 
BRCA2 
 Breast Cancer 
 Ovarian Cancer 
 Pancreatic Cancer 
 Gastric Cancer 
 Gall bladder Cancer 
 Bile duct Cancer 
 Melanoma 
 Male Breast Cancer (more common BRCA2) 
 Prostate Cancer (more common BRCA2) 
ATM  Breast Cancer  Ataxia-telengectasia disease 
p53 
(Li Fraumeni Syndrome) 
 Breast Cancer 
 Soft tissue and Bone Sarcoma 
 Leukemia 
 Brain tumours 
CHEK2 
(Li Fraumeni Sydrome) 
 Same as p53 
PTEN 
(Cowden Syndrome) 
 Breast Cancer 
 Benign breast diseases 
 Digestive tract tumours 
 Thyroid tumours 
 Uterine tumours 
 Ovarian tumours 
CDH1  Breast Cancer (Invasive lobular carcinoma)  Gastric Cancer 
STK11/LKB1 
(Peutz-Jeghers Syndrome) 
 Harmartamous polyps in GI tract 
 Pigmented macules on lips, buccal mucosa, digits 
 Digestive Cancers 
 Cervical Cancer 
 Lung Cancer 
 Testicular Cancer 
 Ovarian Cancer 
 Uterine Cancer 
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Reproductive and Hormonal Risk Factors 
Prolonged exposure to endogenous estrogen has also been shown as an important risk 
factor for breast cancer. For every two-year delay in the onset of menarche, there is a 10% 
reduction in cancer risk8. Moreover, the risk increases as menopause is delayed. The RR 
increases by 1.03% for each year older at menopause9. This was further emphasized when it 
was noted that women that had had a bilateral oophorectomy before the age of 40 had a 50% 
lifetime risk reduction of breast cancer10. 
Data from the Nurses' Health Study suggest that the association is strongest for 
hormone receptor-positive breast cancers. Endogenous hormone levels were measured in 322 
women who developed breast cancer and in 643 age-matched controls without breast cancer. 
When the highest and lowest quartiles of serum hormone concentration were compared, there 
was a significant direct association between breast cancer risk and levels of both estrogens and 
androgens. However, the association was strongest when the analysis was restricted to ER and 
PR-positive tumours, and in situ tumours11.  
Breast density also seems to have an association with breast cancer risk. The denser 
breasts (greater than 75% density) compared to women of the same age with less or no dense 
tissues have five times greater risk of developing breast cancer12 . Both endogenous and 
exogenous estrogen may influence mammographic density. Mammographic density decreases 
after menopause when ovarian function declines. Hormonal replacement therapy, with 
combination of estrogen and progesterone, increases mammographic density 13 , while 
tamoxifen, which has antiestrogenic effect, decreases mammographic density 14 . 
Mammographic density therefore can be regarded as a marker of the effect of estrogen on the 
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breast tissue. To what extent mammographic density is a predictor for both hormone receptor-
positive and hormone receptor-negative tumors is still unclear. 
Pregnancy related factors 
Nulliparous women are at increased risk for breast cancer (RR 1.2-1.7). Moreover, the 
younger the woman at her first time full-term pregnancy the lower the risk. The risk is 20% 
lower if the first birth is at age 20, 10% lower for a first birth at age 25 and 5% higher if the 
first birth is at age 359. 
Exogenous hormone factors 
It is controversial whether or not long-term use of oral contraceptives increases the risk 
of breast cancer and data are conflicting. Long-term hormone therapy replacement with 
estrogen and progesterone has however been shown to increase the risk of breast cancer, 
especially hormone positive cancers. It must be noted, however, that women taking an 
unopposed estrogen therapy have a slightly lower risk15, 16. 
Ionizing radiation 
Exposure to ionizing radiation has been shown to greatly increase the risk of breast 
cancer. Patients who have received radiotherapy treatment for Hodgkin’s lymphoma to the 
chest wall, especially between the ages of 10-16 and up to the age of 45, are at increased risk 
of getting breast cancer17. 
Lifestyle and Dietary Factors 
Women of higher socioeconomic status are at a two-fold greater risk for breast cancer. 
This is thought to be due to differing educational, occupational and economic level reflecting 
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different reproductive patterns with respect to parity, age at first birth, age at menarche and 
utilization of screening mammography.   
In postmenopausal women, it has been shown that a higher body mass index (BMI) is 
associated with a higher risk of breast cancer. Obese postmenopausal women have higher 
estrogen levels than non-obese postmenopausal women, due to the conversion of adrenal 
androgens to estrogens in fatty tissue. In a pooled analysis of seven prospective studies in the 
US, women who weighed at least 80 kg (176 lbs., BMI >33 kg/m2) had a 25% higher risk of 
breast cancer as compared to those weighing less than 60 kg (132 lbs., BMI<21 kg/m2), after 
adjusting for height18. In the same-pooled analysis, the opposite association was found in 
premenopausal women. Those with a BMI≥31 kg/m2 were 46% less likely to have breast 
cancer compared to those women who’s BMI was <21 kg/m2 18. 
Alcohol Intake 
Many dietary risk factors have been evaluated but are quite difficult to interpret with 
regards to a direct causal relationship to breast cancer. Increased alcohol intake is the only 
dietary risk factor that has been consistently shown in several epidemiological studies, to 
increase the risk of breast cancer. More specifically, it increases the risk of hormone positive 
breast cancers and the use of hormone replacement therapy acts as an additive risk factor to 
increased alcohol intake. It is believed that it may be in part due to the increased estrogen and 
androgen levels in women who consume alcohol as well as increased mammary gland 
susceptibility to carcinogenesis and DNA damage in women who consume alcohol 19 .  
Moderate to increased use (≥ three drinks per day) as compared to those who abstain from 
drinking, has been shown to have a 12% increased risk of breast cancer20.   
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In conclusion, most of these risk factors for breast cancer are associated with increased 
exposure to estrogen, whether it be endogeneous or exogeneous. The higher or the longer 
breast tissue is exposed to estrogen, the higher the risk of breast cancer.   
1.3 Molecular Subtypes of Breast Cancer 
 Breast cancer is a heterogeneous and phenotypically diverse disease. Classically, 
pathologic features of the cancer have been used to determine prognosis.  These features 
include the histologic grade of the tumour, the presence of lymphovascular invasion, the 
presence of nodal disease as well the expression of various receptors, namely; ER, PR and 
Her-2-neu. These features have helped sub-categorize breast cancers into different groups with 
different tretment options.  
 However, more recently, due to the progress in molecular profiling and using gene 
expression arrays, Perou et al. further classified these 3 subtypes of breast cancer (ER/PR, 
Her-2 and TNBC) at a genetic level, and characterized other biologic subtypes21,22,23. As these 
different subtypes have distinct responses to therapy, this molecular portrait of breast cancer 
has further helped in determining prognosis, and may eventually aid in treatment strategies. 
 Five different intrinsic subtypes of breast cancer have been identified, each having their 
own distinct genetic profile. 
Luminal Subtype 
 The most common subtype is the Luminal subtype which is further subdivided into 
luminal A and luminal B; making up two distinct intrinsic subtypes. They make up the 
majority of ER+ breast cancers. These tumours typically express luminal cytokeratin 8 and 18 
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and are characterized by their expression of ER, PR and other genes associated with ER 
activation. The subdivision is not only at a molecular level but also corresponds to different 
clinical outcomes prognostically.   
 Luminal A tumours, making up approximately 40% of all breast cancers, usually have a 
high expression of ER-related genes, low expression of HER2 genes and low expression of 
proliferation-related genes. As expected, they correspond to the best prognosis. 
 Luminal B tumours, making up approximately 20% of all breast cancers, have a lower to 
moderate expression of ER-related genes, variable expression of HER2 and a higher 
expression of proliferation genes. They relapse more frequently on antiestorgen/aromatase 
inhibitor therapy and thus have a worse prognosis than luminal A cancers. 
HER-2 enriched Subtype 
 The second most common subtype is the ERBB2-positive or HER2-enriched subtype. 
These make up approximately 10-15% of all breast cancers and are characterized by high 
expression of the HER2 and proliferation gene clusters and a low expression of the luminal 
cluster. They are typically ER-PR-negative. Although this subtype has a poorer prognosis, 
with the advent of targeted therapy against HER2, Herceptin, the outcome of patients has 
greatly improved24. 
Basal-like Subtype 
 The third subtype has been named the Basal-like subtype because of its similarity in 
expression to that of basal epithelial cells. They make up approximately 15-20% of all breast 
cancers. They have low expression of luminal and HER2 cluster genes. These tumours are 
usually ER/PR-negative and HER2-negative. Naming these breast cancers however, “triple-
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negative” is a misnomer. Although most “triple-negative” tumours are basal-like and most 
basal-like tumours are triple-negative, there is a significant 30% discordance between the two 
types. Basal-like tumours have a high expression of the proliferation cluster of genes and are 
almost always histologically high-grade tumours. They demonstrate widespread genomic 
instability and have a high expression of the epidermal growth factor, and basal epithelial 
cytokeratin 5, 14 and 17. Eighty percent of BRCA1 mutation carriers have basal-like 
tumours25. These tumours have a poor prognosis, as they do not benefit from established 
targeted therapies, being mostly receptor negative. However, they do respond to 
chemotherapy, with a complete pathologic response rate of up to 45%, which is promising. 
Claudin-low Subtype 
 The fourth subtype is the non-basal TNBC. This subtype is more uncommon however 
clinically quite significant. They have an extremely low to absent expression of the luminal 
cluster genes and high expression of the epithelial-mesenchymal transition (EMT) genes, 
immune response genes and characteristics reminiscent of stem cells. Many studies have been 
performed regarding the EMT process and suggest its implication in tumour progression and 
spread of metastasis26, which may account for the poor prognosis of TNBCs. These tumours 
tend to respond to chemotherapy at an intermediate level between the basal-like and luminal 
tumours.  
Normal-like Subtype 
 This final subtype is the hardest to characterize clinically, however is always present in 
gene expression arrays. It is difficult to know whether or not this is a true subtype or a 
technical artefact, due to low tumour cell composition of those specifically sampled 
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specimens. It has a similar gene expression pattern as normal breast tissue.   
 Understanding these different intrinsic subtypes has greatly aided in the understanding 
of the biology of these tumours, which can lead to better evaluation of treatment strategies for 
breast cancer.   
1.4 ER/PR-positive Breast Cancer 
 Hormone receptor positive breast cancers are the most common type, making up 
approximately two thirds of all breast cancers. Hormone receptor-positive breast cancer was 
characterized over 40 years ago by Elwood Jensen. He noted that radiolabeled estrogens 
concentrated preferentially in some human breast tumors as well as in estrogen target organs. 
These findings then led to the discovery of the estrogen receptor (ER), as well as the 
progesterone receptor (PR), which were found in high abundance in a large fraction of 
malignant breast tumours. It has since become clear that human breast cancers are dependent 
upon estrogen and/or progesterone for growth and that this effect is mediated through ERs and 
PRs. As mentioned previously, these tumours are now classified as the luminal subtype of 
breast cancers. It is these luminal tumours that will be the focus of this thesis. 
Molecular biology and physiology of the estrogen receptor 
 Estrogens have multiple actions on various sites including the cardiovascular, skeletal, 
immune, gastrointestinal and neural systems; however, their most important action is on the 
reproductive organs27. They reprogram gene expression via the activation of nuclear estrogen 
receptors. These receptors bind to estrogen with high affinity and specificity and function as 
ligand-modulated nuclear transcription factors28,29.   
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 Two ER molecules have been identified, namely ER-alpha (ER-α) and ER-beta (ER-
β)30. The key functional domains in these receptors are the C or DNA-binding domain, which 
binds with high affinity and specificity to specific DNA sequences (estrogen response 
elements (ERE)) in the promoter regions of target genes, and the E or ligand-binding domain, 
which bind estrogens and estrogen analogues31. The ERE in the target genes is a 15-base pair 
inverted-repeat DNA sequence (RGGTCAnnnTGACCY), to which ER dimers bind with high 
affinity and specificity32, with one receptor molecule in contact with each five base-pair 
segment of the response element 33 . The estrogen receptors contain two regions, termed 
activation functions (AF) that mediate the increase in transcriptional activity induced by the 
receptors in the presence of ligand. AF-1, located near the amino-terminal end of the receptor, 
acts independent of ligand, whereas AF-2, located in the ligand-binding domain, is ligand 
dependent34. There are also numerous co-regulator molecules, including RNA cofactors that 
interact with the receptors in a ligand-dependent manner, modulating receptor-mediated 
transcription by interacting with both AF regions and transcription factors associated with 
RNA polymerase II35.  
 When an estrogen or its analogue reaches the cell nucleus and binds to ER, the 
conformation of the ligand-binding domain of the receptor changes, either allowing or 
preventing interaction with the co-activators, depending on whether the ligand is an agonist or 
an antagonist, respectively. The estrogen receptor dimers bind to the ERE in target genes, and 
via agonist-dependent association with co-activators, increases the rate of transcription by 
interacting with and activating necessary components of the transcriptional apparatus. 
Moreover, the ability of steroid hormone receptors to activate transcription of endogenous 
genes likely depends upon their ability to affect chromatin structure. Many steroid hormone 
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receptors interact with coregulator proteins that are implicated in the remodeling of local 
chromatin structure and the acetylation of histones36,37. In fact, enhancement of transcription 
by adding ligand to ER was observed using chromatinized template DNA but not when using 
naked DNA lacking histones38. This is referred to as the genomic classical mode of action 
(Figure 2, p. 15).  
In the genomic non-classical mode of action, ER regulates gene expression without 
interacting with DNA directly. It acts via other transcription factors such as Fos/Jun activating 
protein-1 (AP-1) complex (Figure 2, p.15)39.  
ERs can also function independently of estrogen. Both epidermal growth factor and 
insulin-like growth factor-1, acting via their extracellular membrane bound receptors, can 
stimulate transcription of ER target genes in the absence of estrogen40,41. Therefore, cross-talk 
and signal amplification occurs between growth factor signaling pathways and nuclear 
receptors42. 
  Estrogens also have non-genomic actions. They bind with high affinity to other cell 
components, including plasma membranes. Some effects of estrogen, such as rapid induction 
of MAP kinase and Erk pathways, appear to involve direct action of estrogen receptors at the 
plasma membrane rather than genomic modulation (Figure 2, p.15). As these rapid effects 
occur without ER-gene interaction, they are called "non-genomic," although the signals 
initiated by these mechanisms ultimately result in regulation of genes. These responses are 
observed in diverse tissues, including the cardiovascular system, central nervous system, and 
in breast cancer cells. 
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Figure 2: The different modes of action of ER (Genomic and Non-genomic)  
Estrogens and the mammary gland 
 As female mice mature, the rudimentary ductal tree of the mammary gland elongates in 
response to estrogens and branches in response to progesterone to fill the stroma. In ER-α 
deficient mice, the ducts fail to elongate43. If ER-β is deficient the gland develops normally 
and the mice can nurse their young with a normal lactation function. If both ER-α and ER-β 
are deficient, the phenotype is similar to those mice with ER-α deficiency only, emphasizing 
the importance of ER-α in male and female reproduction44. 
1.5 Hormone Therapy for ER/PR positive breast cancer 
 Currently there are three main anti-estrogen therapies that can be used in the treatment 
of ER+ breast cancer: Tamoxifen, Aromatase Inhibitors (AI) and Fulvestrant. Clinically, 
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Tamoxifen and AIs are the treatments most often used, while fulvestrant is mainly used as 
second line therapy in patients with metastatic disease that have not responded or are 
progressing on standard therapy with Tamoxifen or AIs.  
Tamoxifen  
 Tamoxifen is a competitive inhibitor of estrogen binding to ERs, and has a mixed 
agonist and antagonist activity, depending on the target tissue. It is therefore called a selective 
estrogen receptor modulator (SERM).  
Its physiological effects in postmenopausal women can illustrate this mixed 
antagonist/agonist effect.  Tamoxifen is known to provide some protection against menopausal 
bone loss45 and lowers serum total and low-density lipoprotein-cholesterol concentrations46,47 
via its agonistic properties. This has been shown to lead to less osteoporotic fractures. Whether 
it is protective against cardiovascular disease is still controversial. Other agonistic features 
include the induction of endometrial hyperplasia and the increased risk of endometrial cancer. 
Moreover, Tamoxifen increases the risk of thromboembolic events such as deep vein 
thrombosis and pulmonary embolism as well as increases the risk of stroke and cataracts47. 
The most salient feature, however, of Tamoxifen is its antagonistic properties with 
respect to breast cancer. Among women with ER+ breast cancer, Tamoxifen reduces the risk 
of recurrence and death and prevents the development of contralateral breast cancer when 
given as adjuvant therapy for early stage disease and can provide palliation in patients with 
metastatic disease47,48,49. Other side effects due to is antagonistic properties include hot flashes 
and vaginal dryness. 
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The molecular mechanisms by which SERMs can act as ER agonists in one tissue and 
as antagonists are just starting to be better understood. The change in receptor conformation 
that follows the binding of Tamoxifen to the ER modulates interactions with co-repressors and 
co-activators that are required for ER-mediated gene regulation. Co-activators increase 
transcriptional activity by promoting the interaction between the receptor and the 
transcriptional apparatus and chromatin remodeling 50 , whereas co-repressors restrain ER 
activity, maintaining the receptor in protein/DNA complexes that do not promote transcription 
and favor an inactive conformation of chromatin51. Thus, the main mechanism of action of 
Tamoxifen is the induction of an abnormal receptor conformation and altered recruitment of 
cofactors. The complement of co-activators/co-repressors expressed in different tissues may 
therefore dictate whether the receptor is active or inactive.  
Aromatase Inhibitors 
 The aromatase inhibitors decrease circulating levels of estrogen in postmenopausal 
women by blocking the action of the enzyme, aromatase, which converts androgens to 
estrogens in peripheral tissues52. There are three different AIs used in the clinic, namely, 
Anastrazole, Letrozole and Exemastane. These agents are used in the treatment of 
postmenopausal patients with breast cancer in the adjuvant and metastatic setting. AIs are 
contraindicated in premenopausal women, since they may increase estrogen levels via a 
reduced feedback of estrogen to the hypothalamus and pituitary. This would lead to an 
increase in gonadotropin secretion and stimulation of the ovary, and ultimately to an increased 
concentration of the precursors of estrogens, androgen and increased expression of 
aromatase 53 . Contrary to Tamoxifen, AI’s are not associated with an increased risk of 
thromboembolic events or endometrial cancer, however they do have a similar profile with 
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regards to hot flashes and vaginal dryness and have additional musculoskeletal side effects 
including osteoporosis and arthralgia.   
Fulvestrant 
 Fulvestrant is a selective estrogen receptor down-regulator (SERD). It has a steroidal 
structure that binds competitively to the estrogen receptor (ER), with high affinity, and 
downregulates ER by functional blockade and increased turnover. After binding to fulvestrant, 
degradation of the ER is accelerated, ultimately resulting in a reduction in cellular ER. The 
downregulation of cellular levels of the ER protein results in complete abrogation of estrogen-
sensitive gene transcription. As a pure estrogen antagonist, fulvestrant avoids the risk of 
detrimental side effects of selective ER modulators such as tamoxifen, which has partial 
agonist activity. Due to its unique mode of action, fulvestrant lacks cross-resistance with 
existing agents. Fulvestrant, an antiestrogen classified as an estrogen receptor antagonist 
without known agonist effects is mainly used for the treatment of postmenopausal, hormone 
receptor-positive women with progressive metastatic breast cancer after antiestrogen therapy. 
The main adverse effects associated with therapy are nausea, asthenia, pain, vasodilation and 
headache54,55,56.  
Efficacy of Hormone Therapy 
Multiple randomized clinical trials have been performed to evaluate the efficacy of 
hormone therapy in breast cancer. One of the first trials to demonstrate a benefit for 
Tamoxifen therapy was the NSABP B-14 trial, which compared 5 years of adjuvant 
Tamoxifen to placebo. Since that trial multiple others were performed. In 2011, the Early 
Breast Cancer Trialists Collaborative Group (EBCTCG) performed a meta-analysis of 
 19
randomized trials, which compared tamoxifen versus no endocrine treatment in 
premenopausal and postmenopausal women49. With a median follow-up of 13 years, 
tamoxifen resulted in a reduction in breast cancer recurrence by 39% compared to placebo, 
which translated into a 15-year absolute reduction of 13% (33% versus 46%). This was seen in 
patients with both node-negative and node-positive ER+ breast cancer. There was no effect on 
recurrence for patients with ER-negative breast cancer. It also showed a reduction in risk of 
breast cancer mortality by 30%, which translated into a 15-year absolute reduction of 9% 
(24% versus 33%). The magnitude of benefit was similar in women less than 45 years of age 
and in women between the ages of 55 and 69 years.   
 With regards to AI’s, multiple trials have also been performed. In 2010, the EBCTCG 
performed a meta-analysis of these trials demonstrating the benefit of AI’s compared to 
Tamoxifen57. This meta-analysis showed that, with a mean follow-up of 6 years, treatment 
with an AI as a single agent therapy had a reduction in the risk of recurrence compared to 
Tamoxifen (3% absolute reduction in 5-year risk of recurrence, 12% versus 15%). There was 
no difference between an AI and Tamoxifen with regards to overall survival. A secondary 
analysis, with a mean follow-up of 4 years, evaluated the use of Tamoxifen for 2-3 years and 
then switching to an AI for the last 2-3years to complete 5 years versus staying on Tamoxifen 
for the entire 5 years of treatment. This showed that switching to an AI reduced the risk of 
recurrence by 3% and reduced 5-year breast cancer mortality by 2%. Finally, with regards to 
sequencing therapy, in the National Cancer Institute of Canada Clinical Trials Group MA17 
study, 5 years of AI versus placebo was given to patients who had completed 5 years of 
Tamoxifen. With a median follow-up of 64 months, treatment with letrozole improved disease 
free and overall survival compared to placebo58.  
 20
As already mentioned, Fulvestrant has been shown to be an effective and well tolerated 
treatment for patients with metastatic breast cancer when compared to Tamoxifen and AI’s 
and is especially useful in patients with Tamoxifen resistance55. It, however, has not been 
shown to be superior to Tamoxifen or AIs and is much more costly, explaining its limited use 
clinically. Futher studies are necessary to evaluate its efficacy as adjuvant therapy.  
 Thus, in summary patients with ER/PR positive breast cancer greatly benefit from 
hormone therapy after surgery and in the metastatic setting. Unfortunately, however, despite 
the benefits of these therapies, 40% of patients still recur and eventually succumb to their 
disease. To date, we have an inability to identify which patients will respond and which will 
not. Multiple studies have been performed to understand the resistance mechanisms involved 
with regards to hormone therapy, most of these studying the resistance to Tamoxifen. 
1.6 Resistance to Tamoxifen 
 Research over the last two decades has identified two forms of resistance to Tamoxifen 
therapy: Intrinsic (de novo) resistance, in which ER-negative and many ER+ tumours do not 
respond to Tamoxifen at the outset of therapy, and acquired resistance, where ER+ tumours 
that initially responded to therapy stop responding and may actually exploit the Tamoxifen-ER 
complex as a stimulator as opposed to an inhibitory signal59. As this is quite a complex and 
exhaustive topic this will simply be summarized here. 
Intrinsic Resistance 
 Understandably, it has been noted that ER/PR-negative breast cancers do not respond 
to Tamoxifen therapy.  However, it has also been noted that approximately 25% of ER+/PR+ 
tumours, 66% of ER+/PR- and 50% of ER-/PR+ tumours fail to respond to or develop early 
 21
resistance to Tamoxifen60. A number of factors have been identified that may contribute to the 
intrinsic resistance of Tamoxifen. 
Loss of ER-α expression/function 
 Lack or loss of ER expression could confer resistance. This is the dominant mechanism 
of intrinsic resistance to Tamoxifen, with the majority of ER-/PR- breast cancers not 
responding to Tamoxifen or AIs. Although quite rare (<1%), mutations in coding of the ER 
gene alter the effects of bound anti-estrogens, leading to a hypersensitive receptor, with 
enhanced binding of co-activators in the presence of low estrogen levels. These somatic 
mutations alters the crosstalk between ER-α and various ER-α pathways that normally down-
regulate ER signalling. Such loss of regulation could theoretically enhance ER-mediated cell 
growth and contribute to the development of resistance. Also, epigenetic changes have been 
identified that cause transcriptional inactivation of the ER gene39. 
Altered expression of ER-β 
Although the role of ER-β in Tamoxifen resistance remains unclear, it has been shown 
that relative changes in the expression of the ER isoforms that occur during tumorigenesis 
parallel the marked changes in estrogen action. Interestingly, in an RT-PCR study, the median 
ER-β mRNA levels were approximately 2-fold higher than ER-α levels in tamoxifen-resistant 
tumours compared with tamoxifen-sensitive tumours39. 
Tissue-specific availability of co-activators and co-repressors 
 As already mentioned, when Tamoxifen is bound to an ER it changes the conformation 
of the ligand-binding domain, generating an abnormal receptor conformation, recruiting co-
repressors, and thus leaving ER in an inactive state. In some cells, tamoxifen-induced AF2 
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inhibition may be bypassed when enough co-activator function is recruited to the ligand-
independent domain, AF161. In other cell types, available co-activator proteins might bind to 
and activate AF2 despite the presence of tamoxifen62. 
Modulation of ER expression through second messengers 
 As discussed before, ER can be activated independent of estrogen via growth factor 
signalling. Both ER expression and function correlate with distinct patterns of growth factor 
receptor overexpression. It appears likely that an appropriate growth factor environment is 
necessary for efficient mitogenesis in breast cancer cells, with steroid hormone and growth 
factor signalling pathways "cross talking" to reinforce each others' signalling. One proposed 
model for both primary and secondary hormone resistance in breast cancer is that phenotypic 
changes in growth factor signalling pathways may perturb this balance of steroid hormone and 
growth factor interaction, providing a selective advantage for tumour cell proliferation63, 
potentially explaining the resistance to endocrine therapy in breast cancer. 
As an example, ER- and ER+ but PR- tumours overexpress proteins of the epidermal 
growth factor receptor (EGFR) family, particularly EGFR and the HER2 protein63. Studies 
have shown that ER expression is suppressed when HER2 or EGFR receptor is activated, 
leading to resistance to Tamoxifen64. Others suggest that the antagonist activity of tamoxifen 
on the ER may be diminished via an interaction between HER2 and AIB1, an ER co-
activator65. 
 As another example, when ER is activated by tyrosine kinase receptors in response to 
growth factor stimulation, PI3K (phosphatidyl-inositol-3-OH kinase) catalyses the formation 
of PIP3. One of the downstream targets of this pathway is AKT, whose activation promotes 
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cellular proliferation and anti-apoptotic responses. There is evidence that ERα can bind in a 
ligand-dependent manner with a regulatory subunit of PI3K, leading to the activation of AKT 
and subsequent downstream effects. However the relationship with ER is reciprocal, in that 
PI3K activates AKT, which phosphorylates the ER at serine-167 resulting in ligand-
independent activation. Interestingly, in vitro, elevated levels of AKT confer Tamoxifen 
resistance39. 
 Finally, in the presence of Tamoxifen, ER may interact with the stress-activated protein 
kinase/c-junNH2 terminal kinase pathway (SAPK/JNK) by binding with the AP-1 
transcription complex. Tamoxifen-resistant tumours, compared with estrogen-treated tumours, 
have increased AP-1 dependent transcription and phosphorylated c-Jun and JNK levels. In 
addition, the conversion to a resistant phenotype has been associated with an increase in 
oxidative stress (as measured by increases in superoxide dismutases and glutathione-S-
transferase). It has been shown that tamoxifen resistant tumours have high AP-1 DNA 
binding. This is due to the fact that tamoxifen can induce intracellular oxidative stress, which 
leads to activation of JNK and SAPK, which in turn increase the transcriptional activity of AP-
1. This chain of events may explain the potentiation of the agonistic effects of tamoxifen at 
AP-1 sites in resistant tumours39. 
Modulation of ER-α expression by BRCA1 
 Tamoxifen resistance in patients with the BRCA1 mutation may be due to the fact that 
most of these patients are ER-negative. BRCA1-mutant tumors fail to express ERα due to the 
loss of BRCA1-mediated transcriptional activation of ESR1. Loss of the wild-type BRCA1 
allele, which occurs during neoplastic development in BRCA1 mutation carriers, has a direct 
effect on ESR1 transactivation, resulting in the loss of ERα mRNA and protein expression66. 
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Altered Tamoxifen metabolism 
 Tamoxifen is converted to its active metabolites, endoxifen and 4-hydroxytamoxifen, 
by two rate-limiting enzymes, cytochrome P450 2D6 (CYP2D6) and UDP-
glucuronyltransferase-2B7 (UGT2B7)67,68. Although it was initially thought that CYP2D6 
polymorphisms may confer a relative resistance to Tamoxifen, multiple sub-analyses of 
several clinical trials (IBIS-1, NCCTG, BIG 1-98, ATAC) 69 , 70 , 71 , 72  have not shown a 
difference in outcomes with regards to survival or recurrence for patients that were poor 
versus good metabolizers of the drug. 
Acquired Resistance 
Loss of ER-α expression/function 
 Approximately 20-30% of patients, that initially have ER+ tumours, treated with 
tamoxifen, acquire a resistance via loss of ER-α in the recurrent tumours. It is however 
important to note that even in those patients that relapse under Tamoxifen treatment, 20% of 
them will still respond to an AI or to the full antiestrogen Fulvestrant, suggesting that ER 
continues to regulate tumour growth even in tamoxifen-resistant patients39. 
Co-repressor and co-activator expression levels 
Co-repressor and co-activator expression levels may influence the development of 
secondary resistance to tamoxifen. In animal models, prolonged tamoxifen exposure alters the 
balance between co-activators and co-repressors in favour of the agonist, growth-promoting 
properties of tamoxifen; the net effect is stimulation of growth despite the continued presence 
of tamoxifen73. This is accompanied by suppression of co-repressor N-CoR levels in the 
tamoxifen-stimulated tumours when compared with their tamoxifen-sensitive counterparts74.  
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Growth factor pathways 
 As already mentioned in de novo tamoxifen resistance, growth factor pathway “cross 
talk” also plays a role in acquired tamoxifen resistance. Signalling through EGFR and the 
HER2 receptor appears to bypass the estrogen requirement for breast cancer cell growth and 
may drive initially ER+ cells into an endocrine therapy-resistant state65,75. It is postulated that 
activation of growth factor pathways such as these modulates ER activity via phosphorylation, 
which alters its function, especially its ability to interact with tamoxifen76,77. The net result is 
that an ER+ cell becomes "hormone-independent" and therefore resistant to tamoxifen.   
1.7 DNA Microarray versus RT-QPCR 
 Important goals of cancer research include the discovery of novel cellular targets to 
exploit for novel targeted treatments, new biomarkers for early cancer detection, and to 
provide a better classification of cancers for prognostication and treatment selection. 
 Toward this end, a significant effort has been devoted to understanding the molecular 
basis of carcinogenesis and the biologic behavior of human cancers. Carcinogenesis is a 
multistep process involving genetic and epigenetic events that result in altered expression of 
numerous genes78. Confounding this complexity, many of the so-called oncogenes and tumor 
suppressor genes are signaling molecules, which control the expression of a subset of 
downstream genes. Cells respond to environmental signals by modulating the expression of 
genes contained within the nucleus. When genes are activated, they are transcribed to generate 
messenger RNA, which is transported from the nucleus to the cytoplasm and translated into 
protein by the ribosomes79. 
 Approximately 3 to 5 percent of genes are active in a particular cell, even though all 
cells have the same information contained in their DNA. Most of the genome is selectively 
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repressed, a property that is governed by the regulation of gene expression, mostly at the level 
of transcription (ie, the production of messenger RNA from the DNA). In response to a 
cellular perturbation, changes in gene expression take place that result in the expression of 
hundreds of gene products and the suppression of others. This molecular heterogeneity is 
thought to underlie, at least in part, the variability in outcome and response to therapy that 
characterizes tumors of different histology. Significant variability also exists for tumors of a 
specific histologic type. In general, clinical management decisions and prognostic estimates 
are based solely upon histopathologic analysis of tumor tissue. However, tumor behavior 
cannot be adequately understood through the analysis of one or a small numbers of genes, 
particularly for the common solid tumors79. 
DNA Microarray 
The examination of multiple expressed genes and/or proteins provides more useful 
information for both classification and prognostication of individual tumors. The development 
of microarray methodology, which permits the expression of thousands of genes to be assayed 
simultaneously, represents a powerful technique to read the "molecular signature" of an 
individual patient's tumor. This process is termed gene expression profiling. Analyzing gene 
expression patterns across individual patients with the "same" disease may reveal molecular 
differences. Such classification may allow better treatment selection and prognostication. 
The biggest advantage microarray technology has to offer is the large number of 
transcripts that can be quantified in a single experiment. DNA microarrays are capable of 
making tens of thousands of gene expression measurements simultaneously. Major 
commercial suppliers of DNA microarrays have recently released products in which the entire 
complement of known expressed human genes (the “transcriptome”; approximately 40,000 
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expressed sequences) can be measured on a single microarray. The unprecedented ability to 
monitor the expression of entire genomes has led to biological discoveries that would not have 
been possible by other methods. Nevertheless, microarray technology has limitations including 
its relatively high cost and inability to analyze more than one sample per array experiment80. 
Moreover, analysis of data is quite challenging and based on calculating the ratio of signal 
intensity between tissues based on signaling from fluorescent detectors (eg. tumour vs. 
normal, treated vs. untreated). This tool is best used for the discovery of candidate genes, as it 
analyses thousands of genes at once. Once these genes are discovered however, this smaller 
group of genes is now best suited to be studied using Real-time Reverse Transcription-
Quantitative Polymerase Chain Reaction (RT-QPCR), as this is better suited to analyzing 
multiple samples at once. 
RT-QPCR 
 Real time RT-QPCR is the gold standard by which other methods are compared. This 
technology not only provides a tissue’s genetic profile but it does so in a very quantitative 
method, requiring very small amounts of cDNA. RT-QPCR measures the accumulation of 
PCR product, with each PCR cycle. The main advantage of this method is its relative 
simplicity of experiments as well as the ability to obtain a quantitative result in a single 
reaction. Moreover, hundreds of samples (or genes) can be analysed simultaneously. The 
analytical precision of QPCR is superior to other methods of genetic profiling. Very small 
amounts of cDNA are required to run experiments which is especially useful when extracting 
RNA from formalin-fixed paraffin embedded (FFPE) tissues which often provides a low yield 
of degraded RNA.  
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Interestingly, the capabilities of microarray technologies and RT-QPCR are starting to 
overlap with companies offering high-density microarrays that are designed for the analysis of 
relatively smaller numbers of genes and for high throughput analysis platforms allowing the 
analysis of multiple samples at once. Conversely, companies are making advances in RT-PCR 
technology enabling simultaneous analysis of larger numbers of genes or samples. 
1.8 Predictive versus Prognostic Tools in Breast Cancer 
 As previously mentioned, breast cancer is a heterogeneous and phenotypically diverse 
disease. There are multiple biologic subtypes of breast cancer and they each have a distinct 
behaviour and response to therapy. Classical pathologic and clinical indicators have been 
identified as factors that predict the prognosis of a patient with breast cancer. Such factors 
include age, patient co-morbidity, tumour size, the presence of lymphovascular invasion, high 
grade and poor-differentiation of a tumour as well as nodal involvement.  
However, recently gene expression arrays have been used to identify profiles 
associated not only with good and poor outcomes in breast cancer patients, but also with 
response to specific therapies, such as chemotherapy or anti-estrogen treatment. In our current 
therapeutic model, treatments are not tailored specifically to the individual. There are general 
guidelines for a specific kind of tumour, however, we are unable to predict before treatment if 
patients will benefit or not from the treatments they receive. This leads to some patients being 
over-treated and incurring toxicities needlessly while others are undertreated. Predictive tools 
based on genetic expression arrays, can therefore provide more successful tailored treatments 
for patients.  
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 Predictive tools are based on the actual tumours’ molecular make up to determine 
whether or not they would benefit from a particular therapy. On the contrary, general 
prognostic tools will classify patients based on their gene expression profile into groups of 
good or poor prognosis irrespective of whether they respond to treatment. Importantly, 
characterization of the prognostic or predictive value of a biomarker identified in patients 
undergoing a given treatment requires a control group of non-treated patients, or treated with 
an alternative drug acting via an unrelated mechanism. A pictoral representation of the 
distinction between a predictive versus a prognostic tool can be seen in Figure 3, p.30. 
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B.  
 
Figure 3: Prognostic versus Predictive tools  
A= Prognostic tool (whether untreated or treated, patients are categorized into a high risk versus low 
risk group; B = Predictive tool (will show the likelihood of response to a specific treatment). 
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1.9 Predictive Tools in Breast Cancer 
The two most common gene signatures used clinically today are the 21-gene 
recurrence score (Oncotype DX) 81  and the Amsterdam 70-gene prognostic profile 
(Mammaprint)82. Oncotype DX is a predictive tool whereas Mammaprint is a prognostic tool. 
Multiple studies have shown that although some patients with ER+ tumours derive a benefit 
from adjuvant chemotherapy, the majority do not. Oncotype DX was created to identify the 
subset or ER+, node negative patients who would derive benefit and thus avoid over-treating 
patients who did not. Based on the genetic profile of a patient’s tumour, a recurrence score can 
be calculated and thus guide treatment. Mammaprint aids as a guide for decision-making with 
regards to adjuvant therapy. This tool also based on the genetic profile of a tumour, will 
categorize it as either being a good prognosis or poor prognosis tumour, once again guiding 
clinical decision-making. 
1.10 Development of a gene signature that can predict the response to Tamoxifen 
As already mentioned, two thirds of breast cancers are ER+ and their growth is 
stimulated by estrogens. Adjuvant therapy with anti-estrogens such as Tamoxifen and AIs has 
been shown to increase survival in breast cancer patients. This treatment is, however, not 
successful in all ER-positive tumours, with up to 40% of patients recuring despite completed 
treatment. Tumours can present intrinsic or acquired resistance to Tamoxifen, the mechanisms 
of which were described earlier. However, it is currently impossible to predict which patient 
will benefit from Tamoxifen therapy and which will not. 
 Preliminary studies in Dr. Mader’s lab have identified 20 genes whose expression levels 
in tumours are able to predict the response to Tamoxifen therapy (disease-free survival 
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including local-regional recurrence and metastatic recurrence). These markers, identified using 
bioinformatics analysis of published gene expression datasets, were able to discriminate 
patients that would respond best to Tamoxifen from those that did not. 
 DNA microarray assays performed on the ER+ MCF-7 breast cancer cell line, allowed 
Dr. Mader’s laboratory to identify 170 primary estrogen receptor target genes 83 . 
Bioinformatics tools were thereafter used to demonstrate, using several published datasets of 
breast tumour expression profiles, that levels of expression of these genes in patients’ tumours 
predict outcome for Tamoxifen-treated breast cancer patients. A 20-gene signature was then 
derived from the best estrogen primary target genes combined with genes from unrelated 
signalling pathways found to have individual predictive value and was found to have a 
superior predictive value for Tamoxifen efficacy when tested against the 170-gene 
model84,85,86. This signature’s predictive value was found to be robust in two tumour gene 
expression datasets (Desmedt C et al. 200787, Sortiriou et al. 200688) and independent from 
traditional predictors such as ER/PR and lymph node status (Figure 4, p. 33). This figure 
demonstrates the heatmap and Kaplan-Meier plots for the 20-gene signature.  
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Figure 4: Heat map of the 20-gene signature applied to several published data 
sets demonstrating its ability to predict the response to Tamoxifen 
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 The overall purpose of this study is to develop a PCR kit  (gene signature) to monitor 
expression levels of these 20 genes and ultimately to test this 20-gene signature in a 
retrospective study using paraffin-embedded breast cancer tissues of patients with a known 
medical history. This tool will thus have a direct impact on clinical practice through the 
development of markers of therapeutic success for treatment with Tamoxifen and possibly 
AIs. Futile treatments would be avoided, preventing needless side effects, and improved 
identification of ER+ tumours with a low chance of success to anti-estrogen therapy will 
facilitate research into more appropriate treatments for hormone resistant tumours.  
1.11 Identified Predictive Genes 
The ultimate goal of our study was to develop a 20-gene signature as seen in the 
preliminary results. However, these genes were identified using data sets of Affymetrix micro-
arrays. Knowing that Q-PCR assays may not always reproduce results obtained with micro-
array probes, 10 additional robust predictive genes were identified for validation, so as to 
ensure a final 20-gene signature in the instance where genes could not be validated in Q-PCR.  
Good predictors 
There were 15 genes that were selected as predictors of a good prognosis and good 
response to Tamoxifen therapy. A list of these genes as well as a summary of their function 
can be found in Table II, p. 35. 
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Table II: Genes that predict a good response to Tamoxifen 
Gene Name Function 
ABAT Aminobutyrate Aminotransferase Catalyses conversion of GABA into succinic 
semialdehyde 
COL1A1 Collagen type 1, alpha 1 Collagen found mainly in cartilage 
LTF Lactotransferrin Inhibits solid tumor growth and metastasis 
PPIC Peptidyl-prolyl isomerase C Catalyses a rate limiting step in protein folding 
TNFRSF10B Tumor Necrosis Factor Receptor 
Superfamily 10B 
Apoptotic death of cancer cells 
YAP1 Yes associated protein 1 Encodes protein that binds to SH3 domain of YES 
tyrosine kinase 
RERG Ras-like and Estrogen-regulated 
growth inhibitor 
Inhibits cell proliferation and tumor formation 
SLC1A1 Solute carrier family 1 Transports glutamate across plasma membranes 
DIXDC1 Dix-domain containg protein 1 Inhibits axin-mediated JNK activity 
EGR1 Early growth response 1 Inhibits human cancer cell growth 
PAX2 Paired box gene 2 With ER coactivator NCOA3 compete for binding 
and regulation of ERBB2 transcription 
SLC40A1 Solute carrier family 40, member 1 Duodenal iron export protein 
BMI-1 Leukemia viral BMI-1 oncogene, 
mouse 
Regulating proliferative activity of normal stem and 
progenitor cells 
JUN Jun proto-oncogene DNA, protein, transcription factor binding 
RERGL Ras Superfamily Cell proliferation 
 
Some genes in this group are of particular interest.  Many of them have interesting 
functions in breast cancer, potentially explaining why overexpression of these genes in an ER+ 
breast cancer may predict a better outcome with Tamoxifen treatment.  
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LTF has been shown to inhibit the growth of solid tumours and the development of 
experimental metastases in mice89.  This was then further illustrated when evaluating primary 
breast tumours and their metastases, showing that LTF significantly decreased the metastatic 
potential in breast cancer by inhibiting and thus decreasing cellular motility90.  
TNFRSF10B is among the tumour-necrosis factor receptor superfamily, which is 
associated with its TNF-related apoptosis-inducing ligand (TRAIL) R2. This ligand induces 
the process of cancer cell death/apoptosis. Although one study showed that TRAIL R2 was 
associated with higher-grade tumours, when compared to TRAIL R1, both are involved in 
cancer cell apoptosis and mammary carcinoma could be sensitised to TRAIL-R2-induced 
apoptosis, suggesting that TRAIL-R2 might therefore be used to therapeutically target such 
tumours91. 
There is some suggestion in the literature that YAP1 is a tumour suppressor gene for 
breast cancer and thus if lost, may lead to more progression of breast cancer cells.  In corollary 
therefore, if highly expressed, may lead to cancers with a better prognosis92. 
In a five-gene model predicting the outcome of patients with early ER+ breast cancer, 
RERG overexpression was associated with increased survival and better outcome in patients 
with ER+ cancers treated with Tamoxifen93. This positive correlation has been noted in other 
studies, associating RERG with a better prognosis in breast cancer patients. One study showed 
that high RERG expression correlated with the expression of a set of genes that defined the 
ER+ subtype and was associated with a slow rate of tumour cell proliferation and growth 
inhibition and thus a favourable prognosis for these cancer patients94 . Moreover, RERG 
expression was inversely associated with the proliferation marker MIB1. Strong RERG 
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expression showed an association with longer breast cancer specific survival and distant 
metastasis free interval in a series of luminal type breast cancers and these associations were 
independent of other prognostic variables95.  
PAX2 has been associated with less invasive phenotypes and thus a better prognosis in 
breast cancer. It has been shown that PAX2 activation by estradiol is selectively achieved in 
breast cancer cells of the luminal subtype, via ER, and identifies IGF-1 as a negative 
regulator of PAX2 activity in these cells. Further, a new role for PAX2 in the maintenance of a 
low invasive behavior in luminal breast cancer cells upon exposure to estradiol has been 
revealed, and shows that overexpression and activation of PAX2 in these cells is sufficient to 
reduce their invasive ability96. Another study showed that breast cancers overexpressing PAX2 
were less likely to recur97.  This may be due to PAX2 ability to repress ERBB2 and therefore 
lead to better outcome. PAX2 has been identified in a novel role, as a crucial mediator of ER 
repression of ErbB2 by the anti-cancer drug tamoxifen. PAX2 and the ER co-activator 
NCOA3/SRC-3 compete for binding and regulation of ErbB2 transcription, the outcome of 
which determines tamoxifen response in breast cancer cells. The repression of ErbB2 by ER-
PAX2 links these two important breast cancer subtypes and suggests that aggressive ErbB2 
positive tumours can originate from ER positive luminal tumours by circumventing this 
repressive mechanism. These data provide potential mechanistic insight into the molecular 
basis of endocrine resistance in breast cancer98. 
SLC40A1 has also been shown to predict a better outcome in breast cancer patients. 
SLC40A1 (ferroportin) exports iron out of the cell. Since malignant cells have a high demand 
for iron to grown, upregulation of SLC40A1 which exports iron out of the cell can lead to 
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growth inhibition and decreased risk of metastasis99.  This relationship between SLC40A1 as 
an iron exporter and good prognosis, was reconfirmed in another study by Miller et al.100. 
The role of BMI-1 in breast cancer is uncertain with some studies relating it to a good 
prognosis and others with a poor prognosis. It is especially noted to be a marker of good 
prognosis in ER+ cancers101. However, another study noted that BMI expression was noted 
more often in grade 3 basal-like phenotype, which independently correlated with a worse 
prognosis102. It may be that BMI-1 may play a different role in different subtypes of breast 
cancer. 
Finally, JUN (also known as AP1) has also been implicated in breast cancer to show a 
better prognosis. It has been shown that p12CDK2-AP1 over-expression inhibited in vivo 
tumor growth in immunodeficiency mice, supporting an inhibitory role for p12CDK2-AP1 in 
breast cancer development103.  
Poor predictors 
 There were 15 genes that were selected as predictors of a poor prognosis and poor 
response to Tamoxifen therapy. A list of these genes as well as a summary of their function 
can be found in Table III, p. 39. 
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Table III: Genes that predict a poor response to Tamoxifen 
Gene Name Function 
CCDC90A Coiled Coil domain containing 
protein 90A 
In mitochondria, protein of unknown function 
ERBB2 Erythroblastic leukemia viral 
oncogene homolog 2 
Cell surface receptor similar to EGFR, 
overexpression in Her-2 positive breast cancer 
FOXM1 Forkhead box protein M1 Key role in cell cycle and proto-oncogene among 
many cancers including breast cancer 
NCOA3 Nuclear Receptor Coactivator 3 Stimulates transcriptional activities in hormone 
dependent fashion, overexpressed in breast CA
PGK1 Phophoglycerate kinase 1 Secreted by tumour cells, causing inhibition of 
angiogenesis by release of angiostatin
PRIM1 Primase Polypeptide 1 A subunit of the DNA polymerase complex, 
initiation of DNA replication 
RRAS2 Related Ras viral oncogene 
homolog 2 
Oncogene 
NEDD4L Ubiquitin protein ligase NEDD4-
like 
Links ubiquitin dependent protein degradation to the 
replication-recombination machinery 
TNC Tenascin C Lost as human breast cancer cells develop metastasic 
potential 
ELAVL1 Embryonic lethal abnormal vision 
drosophilia homolog-like 1
Destabilise mRNA and play role in control of gene 
expression
NDRG1 N-MYC downstream regulated gene 1 
Growth arrest and cell differentiation 
NDRG2 N-MYC downstream regulated gene 2 
Neurite outgrowth 
MLLT11 Myeloid/Lymphoid translocated to 11 
Function unknown 
VDAC2 Voltage dependent anion channel 2 
 
Regulates the activity of BAK and connection btw 
mitochondrial physiology and apoptosis 
MYST4 Histone Acetyltransferase MYST4 Plays a role in positive and negative transcription regulation 
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Several of these genes have already characterized functions in breast cancer, 
potentially explaining why overexpression of these genes in an ER+ breast cancer may predict 
a poor outcome with Tamoxifen treatment.  
The upregulation of ERBB2 (Her-2 overexpression) noted in ER+ breast cancers has 
been one explanation of acquired Tamoxifen resistance in ER+ breast cancers and may explain 
the poor outcome to Tamoxifen treated ER+ breast cancers that overexpress ERBB239,104. 
Elevated expression of FOXM1 in breast cancer has been shown to correlate with an 
undifferentiated tumour phenotype and thus a negative clinical outcome. One study showed its 
ability to act as a transcriptional repressor, playing an important role in regulating the 
differentiation of luminal epithelial progenitors. Regeneration of mammary glands with 
elevated levels of FoxM1 was shown to lead to aberrant ductal morphology and expansion of 
the luminal progenitor pool. Conversely, knockdown of FoxM1 resulted in a shift towards the 
differentiated state. FoxM1 mediates these effects by repressing the key regulator of luminal 
differentiation, GATA-3, by promoting methylation of the GATA-3 promoter in an Rb-
dependent manner, identifying FoxM1 as a critical regulator of mammary differentiation with 
significant implications for the development of aggressive breast cancers105. In another study, 
silencing of FOXM1 abolished cell proliferation and overcame acquired Tamoxifen resistance 
suggesting that FOXM1 may contribute to anti-estrogen insensitivity106. 
Patients whose tumours show elevated expression of NCOA3 (also known as AIB1) 
have significantly shorter disease-free and overall survival times after surgery than other 
patients with breast tumours107. Another paper showed that AIB1 plays an important role in 
Tamoxifen resistance, and inhibiting AIB1 significantly restores the sensitivity of Tamoxifen 
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in ER-positive BT474 breast cancer cells108. Convincing clinical studies have shown that high 
levels of HER family member proteins have been associated with relapse after Tamoxifen 
therapy in breast cancer patients that have high AIB1 protein expression109. 
PGK1, a protein involved in glycolysis, was found to be upregulated in HER-2/neu-
positive breast tumours. Increased glycolytic flow and energy production may contribute to 
the acquired resistance to Tamoxifen110. 
RRAS2 is a RAS family member that shares more than 50% amino acid sequence 
identity with classic RAS proteins (HRAS, NRAS, and KRAS). RRAS2 encompasses almost 
identical functional domains to these latter proteins and accordingly shares a number of 
effectors, including RAF1. A link between RRAS2 and Tamoxifen response has already been 
suggested. Silencing RRAS2 leads to sensitivity to Tamoxifen and specifically, high RRAS2 
protein expression in breast tumour biopsies has been shown to correlate with a shorter time to 
relapse in Tamoxifen-treated patients, supporting the case that RRAS2 plays a critical role in 
determining the response to Tamoxifen. 111 . In patients treated with adjuvant Tamoxifen 
monotherapy, high cytoplasmic TC21 (also known as RRAS2) tumor expression has been 
shown to confer an increased recurrence rate. There is growing evidence that crosstalk 
between ER and growth factor signaling contributes to Tamoxifen resistance112.  
TNC is an adhesion-modulating extracellular matrix protein and is highly expressed in 
the microenvironment of most solid tumours including breast cancer and is frequently 
upregulated in a variety of pathological conditions including chronic inflammation and cancer. 
TNC has been implicated in the modulation of cell migration, proliferation, invasion and 
angiogenesis113. The protein has been shown to be involved in a wide variety of processes 
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such as proliferation, epithelial-to-mesenchymal transition, tumor cell migration, invasion, and 
metastasis. TNC is associated with Tamoxifen resistance and shorter metastasis free and 
progression free survival after adjuvant Tamoxifen treatment with lack of clinical benefit from 
first-line Tamoxifen monotherapy. High TNC expression could be a (indirect) marker for a 
defective estrogen response pathway, which would render the cells unresponsive to endocrine 
treatments such as Tamoxifen114. Moreover, breast cancer cells that infiltrate the lungs support 
their own metastasis-initiating ability by expressing tenascin C (TNC). It was found that the 
expression of TNC was associated with the aggressiveness of pulmonary metastasis. Cancer 
cell–derived TNC promotes the survival and outgrowth of pulmonary micrometastases115. 
Higher TNC expression was also shown in invading fronts of breast cancer, correlating with 
poorer patient outcome. It could induce EMT-like change showing loss of intercellular 
adhesion and enhanced migration in breast cancer cells, associated with FAK phosphorylation 
by SRC; this may be responsible for the observed promotion of TNC in breast cancer 
invasion116. 
 Although some studies have shown that NDRG1 and NDRG2 may be associated with 
a good outcome, there are other studies that have shown the opposite. One study showed that 
NDRG1 overexpression was related to shorter disease free survival and a poor prognosis in 
luminal A and triple negative breast cancers117. 
 MLLT11 (also known as AF1Q) overexpression enhanced the in vitro proliferation and 
invasive potential of breast cancer cells. In an in vivo study, it was demonstrated that AF1Q 
transfected breast cancer cells grew much faster and had more pulmonary metastases than 
vector-transfected or its parental counterparts. On the contrary, AF1Q knockdown cells grew 
slower and had less pulmonary metastasis. Taken together, these results provide functional 
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evidences that overexpression of AF1Q leads to more progression in human breast cancer, at 
least in part, through regulating the integrin a3, Ets-1, MMP-2, EFP, and 14-3-3d 
expression118. 
 Finally, VDAC2 inhibits Bak1, which is activated by Bax in mitochondrial apoptosis. 
VDAC2 has also been associated with poor outcome in breast cancer especially in patients 
with supra-clavicular nodal metastases119.  
2. Hypothesis and Objectives 
2.1 Hypothesis 
The main hypothesis is that we can translate this microarray-based signature into a 20-
gene signature PCR tool whose role in predicting the Therapeutic response to Tamoxifen will 
subsequently be tested using a retrospective cohort of patients.  
2.2 Objectives 
 The main objective of this project is to test our hypothesis by developing PCR probes 
against each of these genes and validating their capacity to detect expression predicted by 
micrarray analysis using a panel of breast cancer cell lines. Expression in tumours will also be 
assessed to determine the robustness of the assay in this setting.   
Specific aims: 
(i) To optimise the method of RNA extraction from fresh tissue and formalin-fixed 
paraffin-embedded tumours (FFPE)  
(ii) To correlate the expression levels of the predictive genes in breast cancer cell 
lines between QPCR and Microarray 
(iii) To identify PCR probes that accurately monitor expression levels of our marker 
genes in eight different breast cancer cell lines, fresh tissue and FFPE tumours 
(iv) To determine which housekeeping genes are the most reliable to include in our 
tool 
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(v) To create a low density array card with 20 predictive genes and 4 housekeeping 
genes 
3. Materials and Methods 
3.1 Gene selection 
Gene selection was performed, with standard bioinformatics tools using published data 
sets of breast cancer expression profiles (Affymetrix microarrays) by Slim Fourati, a PhD 
candidate in Dr. Mader’s lab. An overview of how this was done is provided below.   
Initially, tumours were subjected to a training screen which compared Tamoxifen 
treated patients versus patients who did not receive any adjuvant systemic therapy, using 3 
published data sets (Miller LD. et al., 2005; Sotiriou C. et al., 2006; Chin K. et al., 2006)88,120, 
, 121 . Cox proportional regressions were used to identify genes associated with distant 
metastasis-free survival of Tamoxifen-treated patients but not of untreated patients, and an 
interaction test was then performed to assess the statistical significance of this association. 
Genes with a p-value equal to or less than 5% were considered predictors of Tamoxifen 
response. Genes predictive in all 3 data sets were included in the validation process. There 
were a few exceptions to this rule as they were felt to be good candidate genes. TNC, RRAS2, 
PAX2, NCOA3 and LTF were not found in all the training screen datasets, however were 
shown to be predictive in the literature with QPCR in Tamoxifen-treated versus untreated 
patients and thus were kept as candidate genes that merited further study.  
The validation process took the genes that passed the screening test and were then 
applied to 3 other published data sets of Tamoxifen treated patients (Loi S. et al., 2007, Loi S. 
et al., 2008, Zhang Y. et al. 2009)122,86,123. Cox proportional regressions were fit to the 
expression of all candidate genes (identified in the training step) and a likelihood ratio test was 
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used to assess the statistical significance of the association of the candidate genes and distant-
metastasis free survival of tamoxifen treated patients. Genes that remained predictive in at 
least 2 out of 3 datasets were considered validated. From this process 30 predictive genes were 
identified. Table IV (p. 48) describes these genes and details results obtained during the 
selection process. 
 48
Table IV: Identified Predictive Genes 
Gene Name Outcome 
Predictor 
Training 
Screen 
ABAT Aminobutyrate Aminotransferase Good  All 3 data sets 
COL1A1 Collagen type 1, alpha 1 Good All 3 data sets 
LTF Lactotransferrin Good 1 data set 
PAX2 Paired box gene 2 Good 2 data sets 
PPIC Peptidyl-prolyl isomerase C Good All 3 data sets 
TNFRSF10B Tumor Necrosis Factor Receptor Superfamile 10B Good All 3 data sets 
YAP1 Yes associated protein 1 Good All 3 data sets 
RERG Ras-like and Estrogen-regulated growth 
inhibitor 
Good All 3 data sets 
SLC1A1 Solute carrier family 1 Good All 3 data sets 
DIXDC1 Dix-domain containing protein 1 Good All 3 data sets 
EGR1 Early growth response 1 Good All 3 data sets 
SLC40A1 Solute carrier family 40, member 1 Good All 3 data sets 
BMI-1 Leukemia viral BMI-1 oncogene, mouse Good All 3 data sets 
RERGL Ras Superfamily Good All 3 data sets 
JUN (AP1) Jun proto-oncogene Good All 3 data sets 
CCDC90A Coiled Coil domain containing protein Poor All 3 data sets 
ERBB2 Erythroblastic leukemia viral oncogene homolog 2 Poor All 3 data sets 
FOXM1 Forkhead box protein M1 Poor All 3 data sets 
NCOA3 Nuclear Receptor Coactivator 3 Poor 2 data sets 
PGK1 Phosphoglycerate kinase 1 Poor All 3 data sets 
PRIM1 Primase Polypeptide 1 Poor All 3 data sets 
RRAS2 Related Ras viral oncogene homolog 2 Poor 1 data set 
NDRG1 N-MYC downstream regulated gene 1 Poor All 3 data sets 
NDRG2 N-MYC downstream regulated gene 2 Poor All 3 data sets 
NEDD4L Ubiquitin protein ligase NEDD4-like Poor All 3 data sets 
TNC Tenascin C Poor No data sets 
ELAVL1 Embryonic lethal abnormal vision drosophilia homolog-like 1  Poor All 3 data sets 
MLLT11 Myeloid/Lymphoid translocated to 11 Poor All 3 data sets 
VDAC2 Voltage dependent anion channel 2 Poor All 3 data sets 
MYST4 Histone Acetyltransferase MYST4 Poor All 3 data sets 
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3.2 Cell Line Selection 
 Eight breast cancer cell lines were selected to evaluate the expression of the identified 
genes. The cell lines included ER positive lines such as MCF-7, BT-474, T47D, and ZR-75 as 
well as ER negative and Her-2 positive cell lines such as MCF-10F, MDA-MB-231, BT-20 
and SKBR3. This allowed us to determine the variability of the expression of these genes in 
different breast cancer cell lines, to ensure that there is indeed a distinct difference between the 
molecular markers noted in an ER-positive versus an ER-negative or Her-2 positive cancer.  
Table V (p. 49) lists the media that cell lines were cultured in. Cell lines were not treated with 
hormones.  
Table V: Cell lines and culture medium 
Cell Line Culture Medium 
MCF-7 AMEM (with 20 nM of L-glutamine) 10% FBS 
BT-474 DMEM 10% FBS 
T47D DMEM 10% FBS 
ZR-75 RPMI 10% FBS 
MCF-10F DMEM/F-12 10% FBS, 10 ng/mL EGF, 10 µg/mL insulin, 0,5 µg/mL 
hydrocortisone, 100 ng/mL cholera toxin 
MDA-MB-231 DMEM 5% FBS 
BT-20 AMEM (with 20 nM of L-glutamine) 10% FBS 
SKBR3 DMEM 10% FBS 
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3.3 RNA extraction 
Cell lines 
 As previously mentioned, 8 cell lines were selected to evaluate the expression of the 
candidate genes in a variety of subtypes of breast cancer. RNA extraction was performed 
using Trizol Reagent®. The RNA extraction procedure from cell lines can be found in 
Appendix A. 
Fresh Tissue 
 RNA extraction from fresh tissue (human breast cancer samples), which was preserved 
in RNA later, was also performed. Initially this was performed using an ABI protocol 
(Appendix B). However, the RNA yield was extremely low and impure. The main issue with 
this protocol was an inability to homogenize the tissue with mortar and pestle after having 
been placed on dry ice and frozen with liquid nitrogen as indicated by the protocol. Despite 
arduous manual grinding of the tissue to powder, the filter used in the purification step would 
get blocked, leading to loss of most of the RNA. A mechanical homogenizer may have 
facilitated this step and improved RNA extraction.   
We therefore turned to the QIAzol Protocol, already used by the CHUM (Centre 
Hospitalier de l’Université de Montréal) Research Centre. Tissues were homogenized with a 
rotor-stator homogenizer (Dako Medimachine, Appendix C), leading to a much more 
successful RNA extraction and higher yield of material. 
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Formalin-fixed paraffin embedded tissue 
 RNA extraction from FFPE human breast cancer samples was also performed. 
Extracting RNA from FFPE can be challenging for many reasons. First, tissues that have been 
fixed for long periods of time have strong cross-linked bonds that are difficult to break, 
making isolation difficult. With archival FFPE tissues, time of fixation and the use of buffered 
versus non-buffered formalin as well as the age of the paraffin blocks are the main 
determinants of RNA quality124. Formalin fixation results in RNA degradation into small 
fragments and a low overall yield of RNA. Although microarray analysis or transcriptome 
sequencing is challenging, it is still possible to perform reliable Microarray as well as QPCR 
gene profiles with the RNA from FFPE samples 125 , 126 , 127 . A study by Leong et al. 
demonstrated that although RNA isolated from FFPE was relatively more degraded, 80% were 
still deemed suitable for subsequent assay (both DNA Microarray and RT-QPCR) and gene 
profiles generated were comparable to RNA extracted from paired fresh tissues128.  
Initially we used the ABI protocol for FFPE extraction (Appendix D).  Yield was low 
as was quality of the RNA.  An RNA clean up was thus performed however this did not 
improve the quality nor the yield of the RNA. Multiple adaptations were thus attempted to 
improve the quality and the yield of the RNA. It has been shown that longer digestion and 
more agitation may provide a higher yield of RNA from FFPE tissues124. I thus adapted the 
protocol by performing 20-25 minutes of rotation of the samples with xylene before placing it 
at 50°C for three minutes in the Deparaffinization step, as well as increased the digestion time 
to 3 hours at 50°C followed by an incubation at 80°C for 15 minutes. Other additional changes 
were made based on the ABI troubleshooting guide provided. In the Protease Digestion 
process, only 200 μL of digestion buffer was used as opposed to 400 μL. In the Nucleic Acid 
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Isolation process, only 240 μL (instead of 480 μL) of Isolation additive was added to each 
sample and 500 μL (instead of 1.1 mL) of 100% ethanol was added to the mix. Moreover, 
Wash 1 and 2/3 were centrifuged for 2 minutes as opposed to 30 seconds. Finally in the 
Nuclease Digestion process, since RNA yield was low, elution was done with 30 μL of RNase 
free water instead of 60 μL. This improved the 260/280 ratio but not the 260/230 ratio and the 
yield of RNA obtained remained low. 
Due to this, I decided to compare the yield and quality of RNA extraction from FFPE 
tissues using two different protocols and kits (the same paraffin blocks were used in each 
protocol to directly compare them). The ABI protocol as previously mentioned was thus 
compared to the Roche Protocol of RNA Extraction from FFPE (Appendix E). Several 
specific changes were made to the protocols. Firstly, for both protocols, it was felt that the 
total quantity of the slices of the paraffin blocks (80 μm) as well as their thickness (4 x 20 μm 
slices) might have initially been too high to properly melt the wax and obtain good digestion. 
Thus instead of having 4 x 20 μm slices to equal 80 μm total, I decided to use less and thinner 
sections (10 x 5 μm slices equalling a total of 50 μm in each tube).  
The main adaptation differences between the Roche Protocol and the ABI protocol can 
be found in Table VI (p.53). 
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Table VI: Differences between Roche and ABI Protocol for RNA extraction 
from FFPE tissues 
Process Roche ABI 
Deparaffinization 800 μL Hemo-De 1 mL Xylene 
Digestion Overnight incubation at 55°C 3 hour incubation at 55°C 
followed by 15 mins at 80°C 
Drying after deparaffinization Air dried at 55°C for 13 mins Air dried at room temp for 45 
mins 
 
When comparing both protocols, the Roche Protocol had overall a higher yield of RNA 
as well as better quality RNA (especially with regards to the 260/230 ratio on the NanoDrop, 
see results section). It was also further noted that even with the Roche Protocol, higher yields 
still could be achieved if smaller quantities of starting material was used per tube.  I therefore 
used 2 x 5μm slices per tube x 3 tubes for each sample (total tissue amount equalling 30 μm). 
The three tubes were then pooled together to increase the total yield of RNA obtained. 
Therefore the Roche Protocol provided better quality and higher yields of RNA, with less 
starting material from the paraffin block.  Due to these findings, all RNA extractions from 
FFPE tissues were subsequently performed using the Roche Protocol for FFPE RNA 
extraction. The longer overnight incubation period, although more time consuming, may be 
instrumental in providing better RNA for expression profiling assays. 
3.4 Quality Assessment of RNA 
 Once the RNA was extracted it was evaluated via two methods.  First, using the 
NanoDrop® 2000 micro-volume spectrophotometer.  Secondly, using the Agilent 2100 
Bioanalyzer.  These tools evaluate two quality control measures on isolated RNA.  One is to 
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determine the quantity of RNA that has been isolated, the second is the purity and integrity of 
the isolated RNA.  
NanoDrop® 
 The NanoDrop® was used to evaluate RNAs from all forms of tissue (cell lines, fresh 
tissue and FFPE tissue).  It is easy to use and requires very little material.  1 μL of RNA is 
pipetted onto the pedestal and then the arm is closed.  In a few seconds the RNA is analyzed 
and all three measures are calculated.  Nucleic acids are traditionally quantified using UV 
absorption using a spectrophotometer. In its simplest form the absorbance is measured at 260 
and 280 nm. The concentration of nucleic acid can be determined using the Beer-Lambert law, 
which predicts a linear change in absorbance with concentration. The OD at 260 nm is used to 
determine the RNA concentration in a solution, a A260 reading of 1.0 being equivalent to 
about 40 μg/mL of RNA.  RNA has its absorption maximum at 260 nm and the ratio of the 
absorbance at 260 and 280 nm is used to assess the RNA purity of an RNA preparation. Pure 
RNA has an A260/A280 ratio of 1.8-2.1.  Ideally a 260/230 ratio should be around 2.0129.  
Agilent BioAnalyzer 
When using the Agilent Bioanalyzer, the following guidelines are used for the assessment 
of good quality RNA: 
 sharp 18S and 28S peaks with no fragmentation peaks present  
 a 28S/18S ratio of 2.0 
 The sum of the total area under both peaks is at least 20% of the entire 
electropherogram  
 Neither peak is greater than twice the size of the other  
 RNA Integrity number (RNI) of 8-10 is considered pure RNA with good integrity 
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The BioAnalyzer was used to evaluate RNA extracted from cell lines. Since the RNA from 
FFPE tissue is by definition degraded, it would be inappropriate to test the quality of the RNA 
extracted from FFPE tissues using the BioAnalyzer. 
3.5 Reverse Transcription 
 Once RNA is extracted it must be converted to cDNA for use in a Q-PCR.  This is 
done via reverse transcription, which can be primed with either an OligoDT or a Random 
Hexamer. Because mRNA has a polyA tail, OligoDT will attach to the polyA tail and prime a 
full-length copy of the mRNA. For longer messages, a random primer is preferred as it will 
enable reverse transcription of the 5′ ends of long genes, but the resulting cDNAs may not be 
full-length copies of the entire gene. 
Cell Lines 
The exact protocol of reverse transcription that was used for the cell lines can be found 
in (Appendix F). For the cell lines Random Hexamer was used for reverse transcription. 
Fresh Tissue and FFPE tissue   
For the fresh and FFPE tissue, Gene Specific primers were used using an ABI protocol 
(Appendix G).  Gene Specific primers enhance sensitivity by directing all of the RT activity 
to a specific message instead of transcribing everything in the mix.  This is especially helpful 
when small fragments of RNA are being used, which makes this most appropriate for RNA 
extracted from fresh tissue and FFPE tissue.  
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3.6 Q-PCR Probe Selection 
 ABI TaqMan assay probes have all been validated by ABI and contain a 3’ 
oligonucleotide, a 5’ oligonucleotide and a fluorescent marker. They are the only assays that 
can be used on the Low-density array that we have chosen as the platform for our predictive 
tool. Different criteria were used to select the appropriate probes that would best represent our 
30 genes. First, since cDNAs are more retrotranscribed at the 3’ends, Q-PCR TaqMan probes 
were chosen that were closest to the 3’ end as possible. Second, because the RNA from 
patients is often composed of small fragments that are degraded when extracted from paraffin 
embedded samples, probes with a small amplicon length were preferred, ideally not exceeding 
100-120 nt. Finally, gene selection was performed via bioinformatics tools using published 
data sets of breast cancer expression profiles (Affymetrix microarrays); a tool called the 
UMapit Microarray-to-TaqMan® Assays Mapping Tool by ABI was utilized allowing us to 
cross-map the TaqMan assays for our 30 genes that corresponded most closely to those used in 
the Affymetrix Microarray. Using these criteria, the ABI TaqMan assays were chosen and 
used to perform the Q-PCR experiments (Table VII, p. 57). It is important to note that there 
are no introns in the JUN gene, thus it was impossible to choose primers spanning an intron. It 
is noted that the probe used for MLLT11 had a longer amplicon of 142nt, however, it was the 
only probe available. This is most likely due to the fact the probe sequence of MLLT11 is 
unique (no matches with other regions of the genome) and it contains a "normal" frequency of 
GC nucleotides. Moreover, MLLT11 is a short gene (2.2 kb) thus less possibility of probes. 
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Table VII: TaqMan Assays used for the Q-PCR experiments 
Target Acession Number Gene Symbol Closest Inventoried TaqMan 
Assay to 3’ end 
Amplicon 
length 
NM 005180 BMI-1 Hs00180411 m1 105
NM 001031713 CCDC90A Hs00978327 g1 94
NM 000088 COL1A1 Hs01076751 g1 59
NM 033425 DIXDC1 Hs00736707 m1 85
NM 001419 ELAVL1 Hs00171309 m1 75
NM 001005862 ERBB2 Hs99999005 mH 88
NM 002228 JUN Hs01103582 s1 91
NM 002343 LTF Hs00914330 m1 92
NM 006818 MLLT11 Hs00199111 m1 142
NM 012330 MYST4 Hs01043690 m1 71
NM 006534 NCOA3 Hs00180722 m1 59
NM 006096 NDRG1 Hs00608389 m1 69
NM 016250 NDRG2 Hs01045109 gH 90
NM 015277 NEDD4L Hs00969321 m1 90
NM 000278 PAX2 Hs00240858 m1 57
NM 000943 PPIC Hs00181460 m1 66
NM 012250 RRAS2 Hs00273367 m1 108
NM 004170 SLC1A1 Hs00188172 m1 76
NM 014585 SLC40A1 Hs00205888 m1 78
NM 006106 YAP1 Hs00902712 g1 62
NM 002160 TNC Hs01115664 m1 87
NM 003375 VDAC2 Hs00748551 s1 94
NM 000291 PGK1 Hs00943178 g1 73
NM 202002 FOXM1 Hs00153543 m1 72
NM 000946 PRIM1 Hs01096422 g1 74
NM 032918 RERG Hs00262869 m1 85
NM 024730 RERGL Hs00226861 m1 72
NM 000663 ABAT Hs00609436 m1 69
NM 003842 TNFRSF10B Hs00366278 m1 62
NM_001964 EGR1 Hs00152928_m1 72 
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3.7 Q-PCR 
The Protocol used for every Q-PCR experiment was an ABI Protocol (Appendix H). 
The experiments were done using a 24 x 16 well plate (384 well plate). Analysis was 
performed using the SDS 2.2.2 software of the 7900HT Q-PCR machine in the genomics 
platform of the IRIC. The results were then analysed and interpreted with the help of the SDS 
2.2.2 software guidelines (Appendix I). All QPCR curves were individually analyzed. Samples 
were studied in triplicate format. Poor curves were eliminated from the analysis.  
3.8 Selection of Housekeeping genes 
 Housekeeping genes are typically constitutively expressed genes that are required for 
the maintenance of basic cellular function, and are expressed in all cells of an organism under 
normal and pathophysiological conditions. These are included in a multi-gene PCR assay as 
they allow normalisation of the mRNA levels between different samples. However, the 
expression level of these genes may vary among tissues or cells and may change under certain 
circumstances.  
A Q-PCR was performed using the ABI TaqMan Assays of 7 different housekeeping 
genes (PPIA, YWAHZ, ACTB, GAPDH, TBP, 18S and HPRT) tested on the eight different 
breast cancer cell lines. A software program called geNorm analyzed the results. After 
rigorous evaluation (as will be discussed in the results sections), 4 housekeeping genes were 
selected for our tool. A minimum of 3 housekeeping genes is required for reliable results. 
GeNorm is a popular algorithm to determine the most stable reference (housekeeping) genes 
from a set of tested candidate reference genes in a given sample panel. From this, a gene 
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expression normalization factor can be calculated for each sample based on the geometric 
mean of a user-defined number of reference genes130. 
3.9 Creation of a customized Low Density Array 
The following is an overview of the experiments that led to the creation of the Low 
Density Array (LDA) card. Details and findings about these experiments will be further 
discussed in the Results section. The first step was to perform a QPCR using 7 housekeeping 
genes in the 8 selected breast cancer cell lines. This allowed us to select the 4 best 
housekeeping genes based on the lowest varia. The next step was to perform a QPCR using 
the 30 predictive gene TaqMan Assays on the 8 selected breast cancer cell lines. These results 
were then correlated to the Affymetrix Microarray, leading to the elimination of 5 genes. 
Using cDNA (from Gene specific RT), the remaining 25 genes were then tested using the 
TaqMan Assays on RNA extracted from paired FFPE and Fresh tissues of the same tumour. 
These genetic profile expressions were then correlated. These results led to the elimination of 
5 more genes based on variability. This left 20 gene predictors and 4 housekeeping genes to 
include on the final LDA card, our ultimate predictive tool.  
We therefore decided on the 48-gene card (24 genes in duplicates), which can be pre-
loaded with the 20 TaqMan assays of our predictive genes and the 4 TaqMan assays of our 
housekeeping genes. As per ABI’s recommendations, all cards have the 18S housekeeping 
gene occupying one of the ports as part of the tool. Please see Appendix J for the Q-PCR 
Protocol of an LDA card. 
4. Results 
4.1 Selection of Housekeeping Genes   
 RNA extraction was performed on 8 different breast cancer cell lines in duplicates (N1 
and N2 replicates). Table VIII (p.60) describes the quantity and quality of the RNA extractions 
according to the NanoDrop and Agilent BioAnalyzer. Quantity, quality and integrity of RNA 
were all satisfactory for subsequent QPCR analysis. 
Table VIII: Quantity and Quality of RNA extraction from Cell Lines (N1, N2) 
Cell Line N Quantity RNA (ng/μl) A260/280 A260/230 RIN 
N1 411.81 1.90 1.89 9.5 MCF-7 
N2 454.20 1.91 2.03 8.8 
N1 408.92 1.89 2.15 8.3 BT-474 
N2 370.48 1.88 2.31 8.4 
N1 426.80 1.91 1.97 8.2 T47D 
N2 426.87 1.89 2.09 9.1 
N1 415.98 1.88 2.07 9.4 ZR-75 
N2 406.48 1.86 2.20 9.3 
N1 346.84 1.92 1.36 9.2 MCF-10F 
N2 455.15 1.88 2.09 9.3 
N1 364.01 1.91 2.01 9.7 MDA-MB-231 
N2 393.81 1.86 2.31 9.4 
N1 397.80 1.93 1.64 7.7 BT-20 
N2 304.81 1.86 2.12 10 
N1 363.61 1.94 1.95 9.5 SKBR3 
N2 434.16 1.86 2.27 9.4 
NanoDrop Results = Quantity RNA, A260/280, A260/230; RIN = RNA Integrity Number determined by Agilent 
BioAnalyzer 
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 The purpose of the first QPCR experiment was to select the 4 most appropriate 
housekeeping genes to be used for all subsequent QPCR experiments. A Q-PCR was 
performed using the ABI TaqMan Assays of 7 different housekeeping genes (PPIA, YWAHZ, 
ACTB, GAPDH, TBP, 18S and HPRT) tested on the eight different breast cancer cell lines. 
The GeNorm program was then used to analyze the QPCR results. This experiment was 
performed twice (N1,N2) to assess technical variability. The housekeeping genes with a gene 
expression normalization factor, as calculated by the GeNorma alogotrihm, closest to 1 are the 
most stable (see Materials and Methods). Figures 5 and 6 (p. 62-63) illustrate the value each 
housekeeping gene received as well as a diagram describing which housekeeping genes were 
most stable for both the N1 and N2 experiments. 
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Figure 5: GeNorm Results (N1) 
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Figure 6: GeNorm Results (N2) 
The most stable housekeeping genes were ACTB, 18S, PPIA and TBP. Table IX (p. 
64) describes these genes and their function. These 4 genes were thus the best candidates to be 
used as the housekeeping genes in the subsequent QPCR experiments and eventual LDA. In 
order to have reliable results a minimum of 3 housekeeping genes must be used per 
experiment.  
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Table IX: Housekeeping Genes 
Gene Name Function 
18S Ribosomal RNA Ribosomal RNA subunit 
ACTB Actin Beta Mammalian cytoplasmic non muscle actin, involved in 
cellular motility, structure and integrity 
PPIA Peptidyl-prolyl isomerase A Protein folding, intracellular protein transport 
TBP Tata-box binding protein Transcription factor 
 
4.2 Selection of Predictive Genes  
 Using the ABI TaqMan Assays, the 30 predictive genes were evaluated by Q-PCR in 
the 8 different cell lines. Each sample was evaluated in a triplicate fashion. All Q-PCR curves 
were evaluated and poor curves were eliminated from the final analysis. One cell line was 
randomly selected as the calibrator sample to which other samples were compared. In this 
case, MDA-M231 was used as the calibrator sample. The relative quatification (RQ) is the 
fold change. The calibrator is fixed at a value of 1. The other samples have a value that is 
either greater or lower with regards to the calibrator. Almost all genes had a fold change of 
greater than 2 or less than 0.5, which is considered significant (Appendix I). The following 
Heat Maps describe the variations in expression of the 30 predictive genes in the 8 different 
cell lines (Figure 7 (N1) and 8 (N2), p. 65-66). A log scale was used to better discriminate the 
variations in gene expression. Variability was observed between replicates, leading to different 
clustering of the cell lines by the expression levels of the 30 genes. Note that the N2 replicate 
heatmap divides cell lines by ER status (with the exception of BT-20) and thus appears to 
represent more accurately the biology of the tumors.  
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Figure 7: Heatmap results of the 30 Predictive genes in the 8 cell lines (N1)
Legend : Heat representation of the expression of 30 genes in breast cancer cell lines. The level of expression 
of each gene in each sample is represented in a log-space using a pink-blue colour scale. Rows of expression 
matrix, transcripts; columns, profile cell line. Hierarchial clustering (distance : correlation, linkage : ward) 
was used to regroup genes with similar expression patterns 
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Figure 8: Heatmap results of the 30 Predictive genes in the 8 cell lines (N2) 
 
We then compared the patterns of expression obtained using ABI TaqMan Assays (N1 
and N2 profiles) with 5 published Affymetrix microarray expression profiles in breast cancer 
Legend : Heat representation of the expression of 30 genes in breast cancer cell lines. The level of expression 
of each gene in each sample is represented in a log-space using a pink-blue colour scale. Rows of expression 
matrix, transcripts; columns, profile cell line. Hierarchial clustering (distance : correlation, linkage : ward) 
was used to regroup genes with similar expression patterns. 
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cell lines including the same 8 cell lines used in Q-PCR (HoeflichKP_2009, 
HollestelleA_2009, NeveRM_2006, LiedtkeC_2009, CharafeJauffretE_206); a heat map 
representation of the Spearman correlation between PCR and microarray for each gene is 
represented in Figure 9 (p. 68). We observe for most of the genes a positive correlation (red 
colour) between the QPCR experiments (N1 and N2 replicates) and the microarrays. 4 genes 
were eliminated due to a poor correlation with the Affymetrix microarrays: BMI-1, VDAC2, 
RERGL and MYST4. JUN was also eliminated on the basis of the absence of introns in this 
gene, leading to possible contamination by unspliced RNA precursors or by genomic DNA. 
Although PAX2 did not display a good correlation, it remained an interesting gene to study 
further due to its correlation with good outcome in the literature, and thus we decided to keep 
evluating this gene in subsequent experiments. Thus overall, 5 genes were eliminated from 
subsequent QPCR studies, based on this correlation analysis.   
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Figure 9: Correlation between ABI QPCR and Affymetrix Micro-Array of the 
30 predictive genes on the 8 cell lines (N1 + N2) 
 
Legend : Heatmap representation of the correlation of the PCR expression and the microarray expression across 
five breast cancer cell lines data sets. The Spearman corelation of each gene between PCR and microarray is 
represented in a log-space using a pink-blue color scale. Rows of expression matrix, transcripts; columns, 
microarray data set. Affymetrix probesets matching partially the genes are noted with a star (*).   
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4.2 Assessment of expression levels in fresh tissue and FFPE samples 
 As discussed in the methods, extracting RNA from fresh tissue using the ABI protocol 
yielded poor results, especially because homogenization of tissue in this protocol was 
inadequate. RNA was then extracted using the QIAzol CHUM protocol where homogenization 
was performed with the Dako Medimachine which was much more successful. Table X (p.69) 
compares the extraction results of both protocols. 
Table X: Quantity and Quality of RNA extraction from Fresh Tissue (ABI vs. 
CHUM QIAzol Protocol) 
Fresh Tissue Protocol Quantity RNA (ng/μl) A260/280 A260/230 
ABI 113.40 1.30 0.93 Sample 1 
CHUM 214.94 2.00 2.01 
ABI 3.13 2.43 0.1 Sample 2 
CHUM 332.14 1.90 1.94 
ABI 14.98 3.95 0.15 Sample 3 
CHUM 653.65 1.98 2.01 
 
RNA extraction from Formalin-fixed Paraffin Embedded (FFPE) tissues was then 
perfected.  As mentioned in the methods, 2 different protocols (ABI and Roche) were used and 
compared as well as adapted to have the best RNA extraction possible. We used the Nanodrop 
to evaluate the quantity and quality of the RNA extracted. The A260/280 value is the most 
relevant parameter when evaluating the quality of RNA from FFPE tissues. First, we evaluated 
the RNA extraction using the ABI protocol. The yield and quality of the extraction were low 
and so an RNA clean up was performed, and the RNA re-evaluated. This however, did not 
improve the quantity or quality of the RNA. These results can be seen in Table XI (p.70).  
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Table XI: Quantity and Quality of RNA extraction from FFPE (ABI Protocol 
before and after RNA clean-up) 
FFPE Tissue ABI Protocol Quantity RNA (ng/μl) A260/280 A260/230 
Pre clean-up 155.87 2.02 1.38 Sample 1 
Post clean-up 81.43 1.91 2.03 
Pre clean-up 93.63 2.03 0.71 Sample 2 
Post clean-up 99.74 2.06 0.78 
Pre clean-up 19.39 1.53 0.59 Sample 3 
Post clean-up 39.78 1.84 0.74 
Pre clean-up 10.02 1.68 0.38 Sample 4 
Post clean-up 9.53 1.87 0.60 
Pre clean-up 21.95 1.97 0.45 Sample 5 
Post clean-up 14.00 1.89 0.68 
Pre clean-up 36.69 1.32 1.09 Sample 6 
Post clean-up 1.04 1.64 0.82 
Pre clean-up 9.86 2.18 0.40 Sample 7 
Post clean-up 23.20 1.95 0.30 
Pre clean-up 36.52 2.04 0.44 Sample 8 
Post clean-up 34.31 1.85 0.49 
 
As mentioned in the methods, we thus adapted the ABI protocol to enhance the 
quantity and quality of the RNA, by increasing the time of rotation of the samples as well as 
increasing the digestion time. The quality was improved with regards to the A260/280 value, 
however the yield remained low. Table XII (p. 71) shows the results of the extraction of the 
adapted ABI protocol.  
 
 
 
 71
Table XII: Quantity and Quality of RNA extraction from FFPE (Adapted ABI 
Protocol) 
FFPE Tissue Quantity RNA (ng/μl) A260/280 A260/230 
Sample 1 153.45 1.99 0.68 
Sample 2 111.22 1.97 0.96 
Sample 3 11.60 1.90 0.09 
Sample 4 13.88 1.96 0.09 
Sample 5 23.56 1.90 0.83 
Sample 6 24.67 1.85 0.67 
Sample 7 17.94 2.12 0.07 
Sample 8 21.45 2.13 0.08 
Sample 9 14.32 2.02 0.09 
Sample 10 34.86 1.92 0.51 
  
We then extracted the same RNA from FFPE using both the adapted ABI Protocol and 
the Roche Protocol and compared the results.  Not only were the A260/280 as well as the 
A260/230 values better, but curves on the Nanodrop were of better quality with less 
contamination. Overall, the Roche Protocol yielded a better quantity of RNA as well as better 
quality RNA. These results can be found in Table XIII (p.72).  
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Table XIII: Quantity and Quality of RNA extraction from FFPE (ABI vs. Roche 
Protocol) 
FFPE Tissue Protocol Quantity RNA (ng/μl) A260/280 A260/230 
ABI 99.68 2.07 1.01 Sample 1 
Roche 130.43 1.91 1.70 
ABI 140.46 2.00 1.49 Sample 2 
Roche 63.35 2.01 1.89 
ABI 42.21 2.03 0.98 Sample 3 
Roche 66.21 1.91 1.38 
ABI 37.02 1.99 0.55 Sample 4 
Roche 111.75 1.98 1.69 
ABI 50.55 2.03 0.58 Sample 5 
Roche 185.68 2.00 2.06 
ABI 35.43 1.86 0.44 Sample 6 
Roche 149.01 2.01 1.83 
 
These results demonstrate that RNA extracted from FFPE tissues as well as fresh tissue 
is of adequate quality to be used for genetic profiling of tumours. To monitor expression of the 
selected 25 predictor genes in matched fresh and FFPE tissues, we performed a QPCR using 
the TaqMan Assays on RNA extracted from each type of sample for the same tumour. This 
was performed using cDNA from Gene Specific RT. Table XIV (p. 73) describes the quantity 
and quality of the RNA used for these QPCR experiments. 
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Table XIV: Quantity and Quality of RNA extraction from FFPE and Fresh 
Tissue of the same tumour 
Tissue Type tissue Quantity RNA (ng/μl) A260/280 A260/230 
FFPE 111.75 1.98 1.69 Sample 1 
Fresh 380.64 1.97 1.72 
FFPE 149.01 2.01 1.83 Sample 2 
Fresh 348.48 1.99 1.99 
FFPE 77.83 1.87 1.59 Sample 3 
Fresh 332.14 1.90 1.94 
FFPE 185.68 2.00 2.06 Sample 4 
Fresh 653.65 1.98 2.01 
RNA was extracted from Fresh Tissue using CHUM QIAzol Protocol and RNA was extracted from FFPE tissue 
using the Roche Protocol  
 
 Initially we wanted to evaluate if we could achieve a good PCR signal from RNA 
extracted from FFPE tissues as this RNA, although evaluated to be of good purity, can be 
quite degraded. Again, each sample was evaluated in a triplicate fashion. All QPCR curves 
were evaluated and poor curves were eliminated from the final analysis. One sample was 
randomly selected as the calibrator sample to which other samples were compared. In this 
case, sample 6 was used as the calibrator sample. Almost all genes had a fold change of 
greater than 2 or less than 0.5, which is considered significant (Appendix I). The following 
Heatmap illustrates the expression patterns of the 24 predictive genes on 8 tumour samples 
where RNA was extracted from FFPE tissues (Figure 10, p. 75), showing an appropriate signal 
of our genes in downstream QPCR experiments from degraded RNA extracted from FFPE 
tissues, demonstrating that RNA extracted from FFPE can be used in such QPCR experiments 
for analysis. A log scale was used to better discriminate variations in gene expression. We 
note that in this small tumour set, genes associated with a poor response (depicted with a P in 
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Figure 10, p.75) and genes associated with a good response (depicted with a G in Figure 10, 
p.75), did not cluster together. It is important to note that the predictive genes selected were 
meant to idenpendently predict the response to Tamoxifen without necessarily requiring that 
genes cluster together.  In addition, a limitation in this type of analysis is the small sample size 
and not knowing the patient history associated with these particular tumours and whether or 
not they responded to Tamoxifen. Nevertheless, this QPCR experiment demonstrated our 
ability to genetically profile the tumours from RNA extracted from FFPE tissues.  
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Figure 10: Heatmap results of 24 Predicitve genes in 8 different tumour samples 
where RNA was extracted from FFPE tissues 
Legend: Heatmap representation of the expression of 24 genes in tumours (RNA extracted from FFPE tissues). 
The level of expression of each gene in each sample is represented in a log-space using a pink-blue color scale 
Rows of expression matrix, transcripts; columns, profiled samples. Hierarchial clustering (distance: correlation, 
linkage: ward) was used to regroup genes with similar expression patterns. Genes associated with a good 
response are depicted with a G. Genes associated with a poor response is depicted with a P. 
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A QPCR was then performed using the 25 TaqMan assays using the RNA extracted 
from FFPE and Fresh tissue of the same tumour and the expressions were correlated. Gene-
specific reverse transcription was performed on the RNA of these tissues to prepare the cDNA 
used in the QPCR experiments.  
It is important to note that when comparing RNA from FFPE and frozen tissue, the 
average shift in real-time RT-PCR is in the range of 2-5 Ct. In general, average mRNA 
fragment size from FFPE is well below 500 bp, and amplicon sizes of quantitative RT-PCR 
assays should therefore be below 100-120 bp. Of note, the Ct shift between fresh frozen and 
FFPE derived RNA for a given assay even in the optimal size range (<120 bp) may vary from 
less than 2 to 5 Ct, although this Ct shift remains constant for a given assay. These differences 
have to be taken into account especially if RNA transcript levels are directly compared.126.  
Figure 11 (p. 77) demonstrates the distribution of the average Ct between fresh and 
paired FFPE tumours for both N1 and N2 replicates. The mean difference in average Ct was 
1.99, 95% CI (1.60;2.39) which follows the expected Ct shift of 2 to 5 Ct between fresh and 
FFPE derived RNA. Moreover, this remained constant and all genes were affected in the same 
way showing a positive correlation between the Fresh and paired FFPE tissues. Paired t-test 
was performed to assess the significance of the difference in average CT between fresh and 
FFPE tumours and for both replicates the difference was statistically significant (p<0.05).  
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Figure 11: The distribution of the average Ct between fresh and paired FFPE 
tumours (N1 and N2).  
Legend: Boxplot presenting the distribution of average Ct between Fresh and FFPE tumours. (a) Biological 
replicate 1 and (b) biological replicate 2 
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 The QPCR results of the Fresh and paired FFPE tumour samples were then correlated. 
Figure 12 (p. 79) demonstrates that when correcting for the systematic difference in RQ 
between Fresh and FFPE tissues, the Fresh and FFPE samples for the same tumor cluster 
together despite the degradation of the FFPE RNA.  This is a very positive result. When tested 
statistically, the Pearson correlation (r) between fresh and FFPE was r = 0.301 (t-test p = 
0.00232). Similar results were found in an N2 replicate of this experiment. Not all genes were 
re-tested in the N2 replicate as there was not enough tumour tissue (RNA) for a complete N2 
replicate, however we can see in the genes that were retested, the N2 replicate had a very 
positive correlation between fresh and FFPE tissues of the same tissue, actually better than the 
N1 replicate. Figure 13 (p. 80) shows the Pearson correlation between Fresh and FFPE results 
for both the N1 and N2 replicates. 
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Figure 12: Heatmap correlation of the 25 predictive genes between Fresh and 
paired FFPE extracted RNA in different tumour samples. 
 
 
LEGEND: Heatmap representation of the expression of 25 genes in fresh and in FFPE tumours. To correct for the 
expression bias between fresh and FFPE tumors (FFPE tumors present in average lower RQ) each gene in each tissue 
type (Fresh or FFPE) was center to 0 prior to sample clustering.The level of expression of each gene in each sample 
is represented in a log-space using a pink-blue color scale. Rows of expression matrix, transcipts; columns, profiled 
samples. Hierarchical clustering (distance: correlation, linkage: ward) was used to regroup genes and samples w/ 
similar expression pattern. 
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Gene N1 N2 
LTF -0.31787 -0.17837 
RRAS2 -0.25469 0.31452 
PRIM1 -0.15111 -0.12939 
ELAVL1 -0.13652 NA 
TNFRSF10B -0.12876 -0.0085 
SLC40A1 0.121518 NA 
FOXM1 0.127796 0.296491 
DIXDC1 0.142042 NA 
YAP1 0.210701 0.904635 
NCOA3 0.288044 0.460766 
ERBB2 0.367947 0.50277 
ABAT 0.37304 0.426094 
COL1A1 0.514235 0.605639 
NEDD4L 0.556325 NA 
CCDC90A 0.571797 NA 
PPIC 0.571797 0.724778 
PGK1 0.640434 0.905492 
EGR1 0.644288 NA 
NDRG2 0.65043 NA 
PAX2 0.698446 0.591733 
MLLT11 0.756821 NA 
RERG 0.820231 NA 
SLC1A1 0.863587 NA 
NDRG1 0.900493 NA 
TNC 0.923141 NA 
Figure 13: Pearson correlation between paired Fresh and FFPE tissues (N1 and 
N2) NA = N2 replicate not done 
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4.4 Final selection of the gene signature 
 The LDA card that we had chosen has 24 ports in duplicates. In order to have optimal 
internal validity we decided to include 4 housekeeping genes to the signature: ACTB, 18S, 
TBP and PPIA as already discussed. This left 20 predictive genes to choose to include on the 
final LDA card. Based on the correlation between the genetic expression of the tumours 
between RNA extracted from FFPE and Fresh Tissue, 5 other genes were eliminated: LTF, 
PRIM1, RRAS, ELAVL1 and TNFRSF10B. These 5 genes poorly correlated between Fresh 
and FFPE tissues.  
 Table XV (p. 82) describes the final 24 genes that were included on the LDA card. 
There were 4 housekeeping genes, 10 predictors of good outcome and 10 predictors of a poor 
outcome. 
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Table XV: The Final 24 genes on the LDA card  
Gene Role 
ABAT Good Predictor 
COL1A1 Good Predictor 
PAX2 Good Predictor 
PPIC Good Predictor 
YAP1 Good Predictor 
RERG Good Predictor 
SLC1A1 Good Predictor 
DIXDC1 Good Predictor 
EGR1 Good Predictor 
SLC40A1 Good Predictor 
CCDC90A Poor Predictor 
ERBB2 Poor Predictor 
FOXM1 Poor Predictor 
NCOA3 Poor Predictor 
PGK1 Poor Predictor 
NDRG1 Poor Predictor 
NDRG2 Poor Predictor 
TNC Poor Predictor 
NEDD4L Poor Predictor 
MLLT11 Poor Predictor 
18S Housekeeping Gene 
TBP Housekeeping Gene 
PPIA Housekeeping Gene 
ACTB Housekeeping Gene 
 
Discussion and Conclusion 
The main purpose of this study was to create a simple PCR tool that could predict the 
response to Tamoxifen.  Since the predictive biomarkers were derived from microarray 
experiments, we first had to verify the correlation between Q-PCR results and microarray 
expression profiles .  
5.1 Reproducibility between Q-PCR assays and microarray results 
Firstly, the predictive genes in our proposed tool were identified using bioinformatics 
tools based on data sets using the Affymetrix microarray.  Although we would expect that 
QPCR would have similar results to microarray this is not always the case. Our study initially 
evaluated the signal of our predictive genes by QPCR on 8 well-established breast cancer cell 
lines and this was correlated to the Affymetrix microarray for the same genes and cell lines. 
Gene expression was very strongly positively correlated for 25 out of the 30 genes tested. 
Moreover, the expression patterns obtained were able to discriminate between ER+ and ER- 
breast cancer cell lines, although with greater accuracy in one replicate versus the other. 
5.2 Reproducibility of expression profiles between fresh and FFPE samples 
In the clinical setting, breast cancer tissue is often preserved in various forms. In the 
majority of cases, this is archival formalin-fixed paraffin-embedded tissue. In centers with a 
tissue bank, tissue may be fresh flash frozen or fresh preserved in RNAlater. For a predictive 
tool based on gene expression profiles to be used in the clinical setting it must be able to 
profile genes of a tumour regardless of the way the tumour has been preserved. Thus we first 
optimized extraction protocols from both fresh frozen and FFPE samples, and then compared 
expression profiles in different matched fresh/FFPE tumour samples.  
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With regards to fresh frozen tissue, our study showed that the most crucial step in RNA 
extraction is ensuring appropriate homogenization of the tissue prior to extraction. This yields 
both quantity and quality RNA for downstream QPCR experiments. For FFPE tissues, this 
process is more difficult. The bonds created by the formaldehyde as well as the age of the 
paraffin blocks play an important role in the quantity and quality of RNA that can be 
extracted. RNA from FFPE tissues is often difficult to extract and is frequently degraded. Our 
study has shown that the most crucial part of RNA extraction from FFPE tissues is ensuring 
longer digestion periods at elevated temperatures, with overnight digestion leading to the best 
yield of quality and quantity.  
Despite the degradation of the RNA, adequate PCR signalling was obtained in our 
study, and these results were strongly independently positively correlated with fresh tissue of 
the same tumour, further confirming that RNA from archival paraffin blocks can be reliably 
used in PCR experiments, if extracted appropriately. Moreover, PCR assays should be kept 
relatively short in length with an amplicon of less than 120nt and ideally less than 100nt for 
more reliable results. When the correlation between FFPE and fresh tissues was done, 5 other 
genes were eliminated due to a negative or poor correlation between the expression of these 
genes, in fresh tissue versus FFPE of the same tumour. One would expect a similar outcome 
(upregulation or downregulation) of a gene in a tumour regardless of where this RNA was 
extracted from (i.e. Fresh or FFPE). In the case of these five genes, however, this was not 
found. Amplicon size for these genes was adequately small (less than 100nt) and gene specific 
RT was used to make the cDNA, also signal strength for these genes were good when you 
look at the fresh and FFPE tissues individually. Despite this, a positive correlation between the 
expression profile of fresh versus FFPE tissues was not attained. The caveat here is the small 
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sample size. It is known that although QPCR experiments can be performed using RNA from 
FFPE tissues, this is not 100% successful. Further experiments with larger sample sizes are 
needed to confirm these results.  
5.3 Tumour clustering based on gene signature expression patterns  
Our predictive genes did not cluster in good and poor predictors in different tumours 
samples. This may be explained by the method in which the genes were selected in our study, 
as they are independently associated with response to treatment. However, the lack of 
clustering may be due the small tumour sample with unknown clinical history. Ideally this 
experiment should be performed again on more tumour blocks.  
5.4 Rationale for an LDA platform for this tool 
We selected the TaqMan® low-density array (LDA) by Applied Biosystems (ABI) as 
the platform for our tool. There are multiple advantages to using an LDA card as a platform 
for gene expression profiling. LDAs are a novel approach to gene expression profiling. Based 
on real time quantitative-polymerase chain reaction (QRT-PCR), these arrays enable a more 
focused and sensitive approach to the study of gene expression than gene chips, while offering 
higher throughput than more established approaches to QRT-PCR, at a lower cost. The main 
advantage of this tool is that it allows multiple selected genes to be studied from a single 
sample, and also offers savings in terms of materials. On the 24-gene card that we have 
selected we can include 20-21 predictive genes with 3-4 housekeeping genes. As ABI has 
done their own studies of validity on housekeeping genes, all cards have the 18S housekeeping 
gene occupying one of the ports as part of the tool.  
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A study by Goulter and colleagues131 compared LDA’s and showed low variability 
with correlation coefficients close to 1.0. By performing 2-fold and 10-fold serial dilutions of 
cDNA samples in the LDAs they found a clear linear relationship between the gene expression 
data points over 5 orders of magnitude. Furthermore, the data generated by the LDA from a 
cell based pharmacological study were comparable to data generated by conventional QRT-
PCR. The other advantage of LDA is its ability to perform a reliable PCR from amounts of 
cDNA as small as 50-100ng. This is important as RNA extracted from Formalin-fixed paraffin 
embedded (FFPE)-tissues is often degraded and only small amounts of RNA can be retrieved. 
Using an LDA as opposed to a standard QPCR method helps optimize our ability to get a 
reliable expression profile on human tumours requiring very little material. 
5.5 Predictive tools in Breast Cancer 
The two most common gene signatures used clinically today are the 21-gene 
recurrence score (Oncotype DX) and the Amsterdam 70-gene prognostic profile 
(Mammaprint). Oncotype DX is a predictive tool and Mammaprint is a prognostic tool. 
Multiple studies have shown that although some patients with ER+ tumours derive a benefit 
from adjuvant chemotherapy, the majority do not. Oncotype DX was created to identify the 
subset or ER+, node negative patients who would derive benefit and thus avoid over-treating 
patients who did not. Mammaprint aids as a guide for decision-making with regards to 
adjuvant therapy. 
Oncotype DX 
 In the initial steps of creating Oncotype DX, a prognostic tool was created to determine 
which patients with ER+ cancers would recur despite Tamoxifen therapy. In this approach, the 
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investigators started with the 250 most promising candidate genes selected from the literature. 
They then used a reverse transcription polymerase chain reaction (RT-PCR)-based method for 
generating quantitative expression levels of these genes in fixed tissue from 447 patients 
collected from three largely hormone receptor-positive, node-negative datasets. The result is 
the recurrence score (RS), which is actually a mathematical formula that includes 16 genes 
(plus five reference genes) weighted to optimize prediction of distant relapse despite 
Tamoxifen therapy132. 
The RS was validated in an independent dataset derived from 668 samples (from a 
total of 2617) collected in the tamoxifen-treated arm of National Surgical Adjuvant Breast and 
Bowel Project (NSABP) B-14, a prospective randomized clinical trial examining the benefit of 
adjuvant tamoxifen in hormone receptor-positive, node-negative breast cancer133.  
Once the recurrence score was calculated it was applied to patients that had ER+, node 
negative cancers that had received Tamoxifen with or without chemotherapy (NSABP B-20 
trial)134, thus predicting those patients that would respond to chemotherapy. In this study, a 
high RS (greater or equal to 31) predicted benefit of chemotherapy (methotrexate plus 
fluorouracil with or without cyclophosphamide, (CMF) added to tamoxifen (a decrease in 10-
year distant recurrence risk by 28 percent), whereas patients with a low RS derived minimal, if 
any, benefit from chemotherapy135. It is this predictive portion of the tool that is currently 
being used in practice. Interestingly, in this study they showed that often classical pathologic 
markers did not correlate with the recurrence scores obtained from the genetic profiling of the 
tumours. For example, 19% of high-grade tumours had a low RS and 5% of low-grade 
tumours had a high RS.   
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 Interestingly, Oncotype DX was used to evaluate tumours that were treated with 
Aromatase Inhibitors and the RS was still accurate in predicting distant recurrence as a 
prognostic tool, thus demonstrating that the RS can identify relative endocrine insensitivity as 
a general phenomenon, whether it is tumours treated with Tamoxifen or AI’s. It is important to 
note however, that Oncotype DX with regards to hormone therapy is a prognostic tool as 
opposed to a predictive one. It is a predictive tool with regards to chemotherapy. 
Mammaprint 
 With regards to Mammaprint, it was developed in a slightly different manner. As 
already mentioned this is a prognostic tool classifying tumours into a high-risk or low-risk 
category for recurrence. Investigators from the Netherlands Cancer Institute performed a 
supervised analysis of gene expression arrays on frozen tissue from primary breast tumours 
that were used to develop the 70-gene profile136. Of the 98 breast tumour samples, 78 (80%) 
were from node-negative women younger than 55 years, of whom 34 (44%) had developed 
distant metastasis within five years (and 44 had not). The remaining 20 samples were from 
women with hereditary breast cancer, BRCA1 mutations, who tend to develop basal-like 
breast cancers as well as other hereditary features. Supervised analysis of the gene expression 
arrays selected a 70-gene set with 83% accuracy at differentiating those with distant relapse 
versus those without. 
This was then later validated in a larger study with a cohort of 302 patients. Patients 
were under age 60, had node-negative T1 to T2 tumours, were treated without adjuvant 
systemic therapy, and were followed for over 10 years137. The 70-gene signature performed 
independent of clinical variables in predicting time to distant metastasis (hazard ratio, HR 
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2.13) and overall survival (HR 2.63), but not disease-free survival (HR 1.36). Patients in the 
gene signature high-risk group had a 10-year overall survival of 70% versus 90% for patients 
in the gene signature low-risk group137. 
Other genomic tools 
Rotterdam 76-gene signature 
 This gene signature was developed on fresh frozen tissue of 115 tumours that were 
node negative from women who did not receive adjuvant therapy and were followed for 8 
years. Several gene sets were developed, as there were a variety of subtypes including ER- (16 
genes) and ER+ tumours (60 genes). It was then validated in an independent set of 180 node- 
negative, mixed ER+ (84%) and ER- (16%) tumours, showing that with regards to distant 
metastasis-free survival, the prognostic signature was independent of clinical variables and 
those with a poor gene signature were 7.41 times more likely to develop distant metastases 
than those with a good signature. It is important to note however that the ER- group was quite 
small and thus generalizing to this group is difficult. Moreover, this tool is good for predicting 
early recurrence, before 5 years but not as good at predicting late recurrences, as is most often 
seen in patients with ER+ disease87,138.   
Other Genomic Signatures 
 A number of other signatures are in development and for several types of cancers. 
With regards to breast cancer, another prognostic tool that is also potentially predictive, is the 
two-gene signature (HOX13:IL17BR). This was developed using 60 node positive, ER+ 
tumours. This tool was developed to predict recurrence as well as endocrine therapy 
sensitivity. The HOXB13 gene is associated with recurrence, while interleukin 17 is associated 
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with disease free survival139. The difficulty with this test is that when performed on fixed 
tissues it yields mixed results. A refined version of this two-gene signature included a 
proliferative index, called the molecular grade index (MGI), which could be used in fixed 
tissue, improving its prognostic capabilities140. 
 Finally, the other most promising tool is the “wound response” gene signature. This is 
based on the core serum response (CSR) genes, which change expression when cultured 
fibroblasts are activated with serum. This represents the processes of matrix remodelling, cell 
motility and angiogenesis as seen in wound healing, noted as being important with regards to 
cancer growth and the tumour microenvironment. Activation of the CSR genes was examined 
in a 295-patient dataset (used to validate the Amsterdam 70-gene profile). Tumours that 
expressed the wound response signature as compared to those that did not were found in 
multivariate analyses to portend a higher likelihood of distant metastasis and poorer overall 
survival, making it again a prognostic tool141. 
5.6 Clinical Utility of our tool 
Although the prognostic gene signatures are helpful in identifying poor prognosis 
patients and thus may aid in adjuvant treatment selection, so do our traditional pathologic and 
clinical prognostic factors and these are much cheaper to perform. Prognostic tools do not 
directly evaluate the benefit of a treatment, and are unable to identify patients in whom 
treatment may be beneficial or futile, which ultimately may be more clinically useful. Thus 
predictive tools may be more clinically beneficial. The tools thus far have been developed for 
ER+ patients, there are very few tools that are meant for ER-, Her-2+ or triple negative 
patients. 
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Our tool is a predictive, not a prognostic tool and thus can identify patients that would 
best respond to Tamoxifen as well identify those most likely to be resistant and may be 
selected to enter a clinical trial for patients exhibiting hormone therapy resistance.  This tool 
will thus have a direct impact on clinical practice through the development of markers of 
therapeutic success for treatment with Tamoxifen. Futile treatments would be avoided thus 
preventing needless side effects, and improved identification of ER+ tumours with a low 
chance of success to anti-estrogen therapy. This will facilitate research into more appropriate 
treatments for hormone resistant tumours. There are some suggestions that patients with 
hormone resistance may be treated with other targeted therapies. In some patients, chronic 
activation of ER+Her-2+ breast cancer cell lines with heregulin, a ligand for the Her2 receptor 
family, has shown to lead to down-regulation of ER expression and hormone independence76. 
One report suggests that this effect may be mediated by a co-repressor termed metastasis-
associated protein 1 (MTA1) co-repressor and that it can be inhibited by trichostatin A, 
opening the possibility of pharmacologic reversal of resistance to antiestrogen therapy142. 
These types of discoveries are essential in improving the treatment strategies for ER+ cancers. 
Interestingly, Oncotype DX was used to evaluate tumours that were treated with 
Aromatase Inhibitors and the RS was still accurate in predicting distant recurrence as a 
prognostic tool, thus demonstrating that the RS can identify relative endocrine insensitivity as 
a general phenomenon, whether it is tumours treated with Tamoxifen or AI’s. These results are 
promising for our tool as well indicating that our PCR tool may also be applied for patients 
treated with Aromatase Inhibitors. 
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5.7 Limitations 
Although most of the 30 genes were reliable with a good signal, this was not without 
limitations. For various reasons 10 genes were eliminated from the final tool. As already 
mentioned, not all QPCR results correlated with the Affymetrix micro-array and those that 
poorly correlated were eliminated, as the genes were selected as being predictive based on 
microarray expression patterns. Moreover, although some genes had a good profile on cell 
lines, when tested in real human tumours, the QPCR signals were unreliable especially when 
RNA was extracted from FFPE tissues. Moreover this study was performed on a very small 
sample size with an uknown clinical history. Perhaps these genes would have had a better 
signal on different tumours. In order to reliably select genes for future experiments, more 
tissues should be tested and paired as done in this study with FFPE and Fresh tissue of the 
same tumour. 
Ideally we would have tested ER+ breast cancer tumours that were treated with 
Tamoxifen with a known clinical history using our LDA tool to confirm that our tool is 
predictive by creating a recurrence score as was done for OncotypeDx. Unfortunately, there 
was a lack of tumour samples to test in this manner at the time of this project.  
5.8 Future Perspectives 
The purpose of this study was to develop a platform for predictive biomarkers absed on 
gene expression pattercreate the actual tool. Validity of the tool with tumour samples will be 
performed as a future study. Although it would have been ideal to extract the RNA from 
archival samples with a known clinical history, at the current time, there was unexpectedly a 
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shortage of this tissue in order to perform the actual experiment. Archival tissues are being 
sought and identified in order to complete this portion of the project. 
Patient Selection and History 
 Tissues will be obtained from the CHUM-Hôtel-Dieu hospital breast cancer tumor bank, 
from patients that have been followed in two prospective NSABP trials.  We will be using 
tissues from women in the NSABP-B-14 protocol, which compared patients receiving 
Tamoxifen monotherapy vs Placebo and the NSABP-B-27 protocol where each patient 
received Tamoxifen therapy and various chemotherapy combinations. We have access to the 
recorded pathological and clinical data (5-10 years follow-up) of these patients allowing us to 
know the eventual clinical outcome of these patients. The selection of tumors will include 
samples from 30-40 patients with ER-positive tumors who received Tamoxifen therapy and 
have recurred or died after 5-10 years of follow-up versus 30-40 patients with ER-positive 
tumours who received Tamoxifen therapy and show no evidence of disease after 5-10 years of 
follow-up.  This will allow us to distinguish the molecular profile of a cancer that responds 
versus one that does not. 
 The complete consent form and research protocol was written up (Appendix L) and was 
approved by both the Scientific (Appendix M) and Ethics Committees (Appendix N) of the 
Hôtel-Dieu Hospital of the CHUM. 
Creation of Recurrence Score 
Once the gene profiles of patients that have recurred is compared to those that have ot, 
a recurrence score (mathematical algorithm) can be calculated for use as a guide to clinical 
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practice for the use of hormone therapy in patients with ER+ tumours. This is a future 
perspective once the RNA from archival tissue is assessed with our LDA tool. 
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7. Appendices 
 
APPENDIX A. Isolation of RNA using Trizol Reagent 
 
1. Cells Grown in Monolayer 
 Lyse cells directly in a culture dish by adding 1 ml of TRIzol® Reagent (Invitrogen 
Cat. No. 15596-018) to a 3.5 cm diameter dish, and passing the cell lysate several 
times through a pipette.  The amount of TRIzol® Reagent added is based on the area of 
the culture dish (1 ml per 10 cm2) and not on the number of cells present. An 
insufficient amount of TRIzol® Reagent may result in contamination of the isolated 
RNA with DNA. 
 
2. Phase Separation 
 Incubate the homogenized samples for 5 minutes at 15-30°C to permit the complete 
dissociation of nucleoprotein complexes. 
 Add 0.2 ml of chloroform per 1 ml of TRIzol® Reagent 
 Cap sample tubes securely 
 Shake tubes vigorously by hand for 15 seconds 
 Incubate them at 15-30°C for 2-3 minutes 
 Centrifuge the samples at no more than 12,000 x g for 15 minutes at 2-8°C 
 Following centrifugation, the mixture separates into a lower red, phenol-chloroform 
phase, an interphase, and a colorless upper aqueous phase.  RNA remains exclusively 
in the aqueous phase.  The volume of the aqueous phase is about 60% of the volume of 
the TRIzol® Reagent used for homogenization.  
 
3. RNA Precipitation 
 Transfer the aqueous phase to a fresh tube 
 Precipitate the RNA from the aqueous phase by mixing with isopropyl alcohol.  Use 
0.5 ml of isopropyl alcohol per 1 ml of TRIzol® Reagent used for the initial 
homogenization. 
 Incubate samples at 15-30°C for 10 minutes 
 Centrifuge at no more than 12,000 x g for 10 minutes at 2-8°C.  The RNA precipitate, 
often visible before centrifugation, forms a gel-like pellet on the side and bottom of the 
tube. 
 
4. RNA Wash 
 Remove the supernatant 
 Wash the RNA pellet once with 75% ethanol, adding at least 1 ml of 75% ethanol per 1 
ml of TRIzol® Reagent used for the initial homogenization. 
 Mix the sample by vortexing 
 Centrifuge at no more than 7500 x g for 5 minutes at 2-8°C.   
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5. Redissolving the RNA 
 At the end of the procedure, briefly dry the RNA pellet (air-dry for 5-10 minutes).  It is 
important not to let the RNA pellet dry completely as this will greatly decrease its 
solubility. 
 Dissolve RNA in RNAse-free water by passing the solution a few times through a 
pipette tip 
 Incubate for 10 minutes at 55-60°C, store at -70°C. 
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APPENDIX B.  ABI Protocol – RNA Extraction from Fresh tissue 
 
1. Liquid nitrogen pre-processing 
 Remove the tissue sample from storage and place on dry ice. 
 Place the amount of tissue sample to be processed (0.1 to 3 g) in a pre-cooled (–80 °C), 
clean mortar. 
 Freeze the tissue sample thoroughly by adding a small volume (5 to 20 mL) of liquid 
nitrogen. 
 Allow most of the liquid nitrogen to evaporate, leaving 1 to 2 mL. 
 Grind the tissue with a pre-cooled (–80 °C) pestle until a fine powder is obtained. 
 IMPORTANT! Make sure the tissue sample remains frozen at all times by adding 
more liquid nitrogen if necessary 
 Aliquot the greater of 200 μL or 10–12 μL/mg of tissue Lysis/Binding Solution into a  
wide-mouth container. 
 Using a pre-cooled (–80 °C) metal spatula/scoop, transfer the powder to a pre-weighed 
and cleaned sterile 50-mL tube and into the premeasured Lysis/Binding Solution, then 
mix rapidly. 
 
2. Collect the cells and remove the culture medium 
 Suspension cells: pellet the cells at low speed, and discard the culture medium. 
 Adherent cells: aspirate and discard the culture medium from the culture vessel or 
trypsinize cells to detach them from the growing surface 
 
3. Lysis and Binding 
 Add 200–700 μL Lysis/Binding Solution to 100–107 cells and vortex or pipette the 
lysate up and down several times to completely lyse the cells and to obtain a 
homogenous lysate. Cells will lyse immediately upon exposure to the solution. Use the 
low end of the volume range (~200 μL) of Lysis/Binding Solution for small numbers 
of cells (hundreds), and use closer to 700 μL when isolating RNA from larger numbers 
of cells (millions). 
 
4. RNA Isolation 
 Heat an aliquot of Elution Solution (typically ~50–200 μL per prep) in an RNase-free 
microcentrifuge tube in a heat block set to 70–80°C. 
 Ensure that filter cartridges are adequate with glass fiber filter down at the bottom of 
the cartridge 
 Lysate should be somewhat viscous but not too viscous.  If too viscous homogenize 
further or add more lysis/binding solution and homogenize further 
 Centrifuge at top speed for 2-3 minutes to remove debris (optional) 
 Add an equal volume of 64% Ethanol to the lysate and mix gently but thoroughly by 
carefully pipetting or vortexing, or by inverting the tube several times. 
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 Apply the lysate/ethanol mixture (from the previous step) to a Filter Cartridge 
assembled in a Collection Tube. The maximum volume that can be applied at one time 
is ~700 μL. 
 Centrifuge at RCF10,000–15,000 x g (typically10,000–14,000rpm) for ~15 sec–1 min 
or until the lysate/ethanol mixture is through the filter. 
 Discard the flow-through and reuse the Collection Tube for the washing steps. 
 Repeat as necessary with ~700 μL aliquots until all of the sample has been drawn 
though the filter. Generally up to ~2 mL of sample mixture can be passed through the 
filter without clogging or exceeding its RNA binding capacity. 
 Apply 700 μL Wash Solution #1 to the Filter Cartridge. 
 Draw the washes through the filter as in the previous step. Discard the flow-through 
and reuse the tube for subsequent washes. 
 Add 500 μL Wash Solution #2/3. Draw the wash solution through the filter as in the 
previous step. 
 Repeat with a second 500 μL aliquot of Wash Solution #2/3. 
 After discarding the wash solution, continue centrifugation, or leave on the vacuum 
manifold for ~10–30 seconds to remove the last traces of wash solution. 
 Put the Filter Cartridge into a fresh Collection Tube. 
 Pipet 40-60 μL of Elution Solution preheated to ~70–80°C to the center of the filter. 
Close the cap of the tube. 
 Recover eluate by centrifugation for ~30seconds at room temperature (RCF 10,000–
15,000 x g). 
 Add a second aliquot of hot Elution Solution to the center of the filter and re-spin for 
~30 seconds. Typically, this second elution is collected into the same tube as the first 
elution. 
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APPENDIX C.  RNA Isolation from Fresh Tissue using QIAzol 
 
Important points before starting 
 Do not allow tissue to thaw during weighing or handling prior to disruption in QIAzol 
Lysis Reagent. 
 Homogenized tissue lysates (in QIAzol Lysis Reagent, step 4) can also be stored at -
70°C for at least 1 month 
 To process frozen lysates, thaw samples at room temperature or at 37°C in a water bath 
until they are completely thawed and salts in the lysis buffer are dissolved.  Avoid 
extended treatment at 37°C, which can cause chemical degradation of the RNA. After 
thawing continue with step 5. 
 
1. Use 1 ml of QIAzol Lysis Reagent for up to 100 mg tissue.  The volume of the tissue 
sample should not be more than 10% of the volume of QIAzol Lysis Reagent used. 
Calculate the correct amount and pipet it into a appropriate vessel from homogenization 
and subsequent centrifugation. 
 
2. If the entire piece of tissue can be used for RNA isolation, place it directly into the QIAzol 
Lysis Reagent, and proceed immediately with step 3. 
 If only a portion of the tissue is to be used, determine the weight of the piece to be 
used, and place it into the QIAzol Lysis Reagent and then proceed immediately with 
step 3. 
 Frozen tissue should not be allowed to thaw during handling. The relevant procedures 
should be carried out as quickly as possible. 
 
3. Homogenize immediately using a conventional rotor-stator homogenizer until the sample 
is uniformly homogeneous (usually 20-40 seconds) 
 NOTE: Incomplete homogenization will lead to significantly reduced yields of RNA. 
Homogenization with roto-stator homogenizers generally results in higher total RNA 
yields than with other homogenization methods. 
 For samples containing a relatively high content of fat, proteins, polysaccharides, or 
extracellular material, centrifuge the homogenate at 12,000 x g for 10 minutes at 4°C 
in order to remove insoluble material. Carefully transfer the supernatant into a new 
collection tube and proceed to step 3. 
 
4. Place the homogenate on the benchtop at room temperature for 5 minutes. This step 
promotes dissociation of nucleoprotein complexes. 
 
5. For every 1 ml of QIAzol Lysis Reagent used in step 1 add 0.2 ml of chloroform.  
 Cap the homogenate securely and shake it vigorously for 15 seconds 
 
6. Place the homogenate on the benchtop at room temperature for 2-3 minutes 
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7. Centrifuge at 12,000 x g for 15 minutes at 4°C. 
 After centrifugation, the sample separates into 3 phases: an upper, colorless aqueous 
phase containing RNA; a white interphase; and a lower, red organic phase. The volume 
of the aqueous phase is approximately 60% of the QIAzol Lysis Reagent used in step 
1. 
 
8. Transfer the upper aqueous phase to a new collection tube. Fro every 1 ml of QIAzol Lysis 
Reagent used in step 1, add 0.5 ml of isopropanol. Mix thoroughly by vortexing. 
 
9. Place the tube on the benchtop at room temperature for 10 minutes 
 
10. Centrifuge at 12,000 x g for 10 minutes at 4°C 
 
11. Carefully aspirate and discard the supernatant. 
 The RNA pellet is often visible as a gel-like or white pellet at the bottom of the 
collection tube 
 
12. For every 1 ml of QIAzol Lysis Reagent used in step 1, add at least 1 ml of 75% ethanol. 
Centrifuge at 7500 x g for 5 minutes at 4°C. 
 If the RNA pellet floats or sticks to the side of the collection tube, bring it to the 
bottom of the tube by centrifuging at 12,000 x g for 5 minutes at 4°C. 
 
13. Remove the supernatant completely and briefly air dry the RNA pellet.  Do not dry the 
RNA using a vacuum. 
 
Redissolve the RNA in an appropriate volume of RNAse free water. Purify the RNA 
following the RNeasy mini, midi or maxi RNA cleanup protocol. 
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APPENDIX D. RNA Isolation from FFPE – ABI Protocol 
          RecoverAll Total Nucleic Acid Isolation 
 
A. Before you begin 
 
RNase precautions 
 
Lab bench, pipettors, microtome blade, and cutting surface 
Before working with RNA, it is always a good idea to clean the lab bench, pipettors, and 
sectioning equipment with an RNase decontami- nation solution (e.g., Ambion® RNaseZap® 
Solution, P/N AM9780). 
      
Gloves and RNase-free technique 
Wear laboratory gloves for this procedure; they protect you from the reagents, and they protect 
the RNA from nucleases that are present on skin. Use RNase-free pipette tips to handle the kit 
reagents, and avoid putting used tips into the reagent containers. 
   
 
Prepare Wash Solutions  
a. Add 42 mL of ACS grade 100% ethanol to the bottle labeled Wash 1 Concentrate. Mix 
well. 
b. Add 48 mL of ACS grade 100% ethanol to the bottle labeled Wash 2/3 Concentrate. Mix 
well. 
c. Cap the wash solution bottles tightly to prevent evaporation.  
d. Mark the labels to indicate that the ethanol has been added. 
 
The final solutions will be referred to as Wash 1 and Wash 2/3 in the procedure. 
 
B. Deparaffinization  
 
1. Cut 5-20 μm FFPE sections to obtain the equivalent of ≤80 μm  
o Use sections that were cut by a microtome from the interior of the paraffin 
block, to minimize nucleic acid damage by exposure to the atmosphere during 
storage 
o Place the equivalent of ≤80 μm of tissue slices (i.e., a maximum of four-20 μm, 
eight-10 μm, or sixteen-5 μm slices) in a 2 ml microcentrifuge tube. 
 
2. 100% Xylene, mix, and incubate 
o Xylene treatment completely removes paraffin from the sections 
o Add 1 ml of 100% xylene to the sample 
o Vortex briefly to mix 
o Heat the sample for 3 mins at 50°C to melt the paraffin 
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3. Centrifuge 
o Centrifuge the sample for 2 mins at room temperature and maximum speed to 
pellet the tissue 
o If the sample does not form a tight pellet, recentrifuge for an additional 2 mins.  
If a tight pellet still does not form, proceed with caution in next step. 
o Remove the xylene without disturbing the pellet. Discard the xylene. If the 
pellet is loose, you may need to leave some xylene in the tube to avoid 
removing any tissue pieces. 
 
4. Wash 
o The ethanol washes remove xylene from the sample and accelerate drying of 
the tissue 
o Add 1ml of 100% ethanol (room temp) to the sample and vortex to mix 
o Centrifuge the sample for 2 mins at room temp and maximum speed to pellet 
tissue 
o Remove and discard the ethanol without disturbing the pellet 
o The ethanol will contain trace amounts of xylene, and must be discarded 
accordingly 
o Repeat the above steps to wash a second time with 1 ml of 100% ethanol 
o Briefly centrifuge again to collect any remaining drops of ethanol in the bottom 
of the tube. Remove as much residual ethanol as possible without disturbing the 
pellet. 
o Vacuum dry pellet for 10-15 mins 
 
C. Protease Digestion 
 
1. Digestion for RNA-only isolation 
o Add 400μl Digestion Buffer to each sample 
o Add 4 μl Protease to each sample 
o Swirl the tube gently to mix and to immerse the tissue. If tissue sticks to the 
sides of the tube, use a pipet tip to push it into the solution, or briefly centrifuge 
to bring the tissue down into the solution 
 
2. Incubation 
o Incubate the sample in a heat block or a water bath for 3 hours at 50°C 
 
D. Nucleic Acid Isolation 
 
1. Isolation Additive 
o Add 480 μl Isolation Additive to each sample 
o Vortex the mix 
o The solution should appear white and cloudy after mixing  
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2. Ethanol 
o Add 1.1 ml 100% ethanol to each sample. Pipet in two aliquots of 550 μl to 
accommodate adjustable pipettors. 
o Mix each sample by pipetting up and down carefully. The solution should 
become clear at this point. Be careful when closing lids as the tubes will be 
near capacity. 
 
3. Filter 
o For each sample, place a Filter Cartridge in one of the Collection tubes 
supplied. 
o Pipet 700 μl of the sample/ethanol mixture from step 2 onto the Filter Cartridge 
and close the lid 
o To prevent clogging of the filter, avoid pipetting large pieces of undigested 
tissue onto the Filter Cartridge. 
o Centrifuge at 10,000 x g for 30-60 sec to pass the mixture through the filter 
o Discard the flow-through, and re-insert the Filter Cartridge in the same 
collection tube 
o Repeat the above steps until all the sample mixture has passed through the filter 
(this should take 3 passes) 
 
4. Wash 1 
o Add 700 μl of Wash 1 to the Filter Cartridge 
o Centrifuge for 30 sec at 10,000 x g to pass the mixture through the filter 
o Discard the flow-through and re-insert the Filter Cartridge in the same 
collection tube   
 
5. Wash 2/3 
o Add 500 μl of Wash 2/3 to the Filter Cartridge 
o Centrifuge for 30 sec at 10,000 x g to pass the mixture through the filter 
o Discard the flow-through and re-insert the Filter Cartridge in the same 
collection tube   
o Spin the assembly for an additional 30 sec to remove residual fluid from the 
filter 
 
E. Nuclease Digestion and Final Nucleic Acid Purification 
1. RNA Isolation 
o Combine the following solutions (amount per reaction) to make the DNase mix 
(a master mix can be used if there is more than one sample): 
 6 μl 10X DNase Buffer 
 4 μl DNase 
 50 μl Nuclease-free Water 
o Add 60 μl of the DNase mix to the center of each Filter Cartridge. 
 x
o Cap the tube and incubate for 30 mins at room temp (22-25 °C) 
 
2. Wash 1 
o Add 700 μl of Wash 1 to the Filter Cartridge. 
o Incubate for 30-60 secs at room temperature. 
o Centrifuge for 30 secs at 10,000 x g. 
o Discard the flow-through, and re-insert the Filter Cartridge in the same 
Collection Tube. 
 
3. Wash 2/3 
o Add 500 μl of Wash 2/3 to the Filter Cartridge. 
o Centrifuge for 30 secs at 10,000 x g 
o Discard the flow-through, and re-insert the Filter Cartridge in the same 
Collection Tube 
o Repeat these steps to wash a second time with 500 μl of Wash 2/3 
o Centrifuge the assembly for 1 min at 10,000 x g to remove residual fluid from 
the filter. 
 
4. Elute 
o Transfer the Filter Cartridge to a fresh Collection Tube. 
o Apply 60 μl of Elution Solution or nuclease-free water to the center of the filter 
and close the cap 
o For RNA isolation, use room temperature eluent (22-25 °C) 
o Allow the sample to sit at room temperature for 1 min 
o Centrifuge for 1 min at maximum speed to pass the mixture through the filter. 
The elute contains the RNA 
o Store the nucleic acid at -20 °C or colder 
o (Optional) To store your sample for an extended period of time, or if a very 
small amount of nucleic acid was recovered, transfer the eluate to a non-stick 
tube to prevent loss of the nucleic acid. 
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APPENDIX E.  RNA Isolation from FFPE – Roche Protocol 
           High Pure RNA Paraffin Kit 
 
A.  Before you begin 
o Sample material: 5-10 μm sections from formalin-fixed paraffin embedded tissue 
o During fixation in formalin intracellular RNAses become inactivated. However, 
RNA is degraded and cross-linked to proteins or inter- or intra-molecularly.  
o Therefore FFPE tissue can be stored at room temp. 
o It is recommended to use sterile disposable polypropylene tubes and tips in order to 
avoid RNase contamination. 
o Wear gloves during the procedure. 
 
B. Preparation of Working Solutions 
o Proteinase K – Dissolve Proteinase K in 4.5 ml Elution Buffer, Store at –15 to -
25°C 
o Wash Buffer I – Add 60 ml absolute ethanol to Wash buffer, Store at +15 to +25°C 
o Wash Buffer II – Add 200 ml absolute ethanol to Wash Buffer, Store at +15 to 
+25°C 
o DNase I – Dissolve DNase I in 800 μl Elution Buffer and mix thoroughly, Store at 
–15 to -25°C 
 
C. Deparaffinization 
o To 5-10 μm sections in a 1.5 ml reaction tube add 800 μl Hemo-De, incubate 5 
minutes and mix overhead during incubation several times. 
o Add 400 μl absolute ethanol and mix. Centrifuge for 2 mins and maximum speed 
(12,000 – 14, 000 x g) and discard supernatant. 
o Add 1 ml absolute ethanol and mix by overhead shaking. Centrifuge for 2 mins at 
maximum speed and discard supernatant. 
o Blot the tube briefly onto a paper towel to get rid of ethanol residues. Dry tissue 
pellet for 10 mins at 55°C.  
 
D. RNA Isolation 
1) If necessary 3 preparations can be pooled after step 4. To one tissue pellet 
(deparaffinized as described above) add 100 μl Tissue Lysis Buffer, 16 μl 10% 
SDS and 40 μl Proteinase K working solution. Vortex briefly in several intervals 
and incubate overnight at 55°C. 
2) Add 325 μl Binding Buffer and 325 μl absolute ethanol. Mix gently by pipetting up 
and down. 
3) Combine High Pure filter tube and the collection tube and pipet the lysate into the 
upper reservoir. 
4) Centrifuge for 30 s at 8000 x g in a microcentrifuge and discard the flow through. 
Steps 3-4 can be repeated, in case RNA needs to be pooled, with two more tissue 
pellet preparations. 
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5) Repeat the centrifugation at maximum speed in order to dry the filter fleece 
completely. 
6) Add 500 μl Wash Buffer I working solution to the upper reservoir. Centrifuge for 
15 s at 8000 x g, discard the flow-through. 
7) Add 500 μl Wash Buffer II working solution to the upper reservoir. Centrifuge for 
15 s at 8000 x g, discard the flow-through. 
8) Add 300 μl Wash Buffer II working solution, centrifuge for 15 s at 8000 x g, 
discard the flow through. 
9) Centrifuge the High Pure filter for 2 mins at maximum speed. 
10)  Place the High Pure filter tube into a fresh 1.5 ml reaction tube, add 90 μl Elution 
Buffer. Centrifuge for 1 min at 8000 x g. 
11)  Add 10 μl DNase Incubation Buffer, 10X and 1.0 μl DNase I working solution to 
the eluate and mix. Incubate for 45 mins at 37°C. 
12)  Add 20 μl Tissue Lysis Buffer, 18 μl 10% SDS and 40 μl Proteinase K working 
solution. Vortex briefly. Incubate for 1h at 55°C. 
13)  Add 325 μl Binding Buffer and 325 μl absolute ethanol. Mix and pipet into a fresh 
High Pure filter tube with collection tube. 
14)  Centrifuge for 30 s at 8000 x g in a microcentrifuge and discard the flow-through. 
15)  Repeat the centrifugation at maximum speed in order to dry the filter fleece 
completely. 
16)  Add 500 μl Wash Buffer I working solution to the upper reservoir. Centrifuge for 
15 s at 8000 x g, discard the flow-through. 
17)  Add 500 μl Wash Buffer II working solution. Centrifuge for 15 s at 8000 x g, 
discrd the flow-through. 
18)  Add 300 μl Wash Buffer II working solution. Centrifuge for 15 s at 8000 x g, 
discrd the flow-through. 
19) Centrifuge the High Pure filter for 2 mins at maximum speed. 
20) Place the High Pure filter tube into a fresh 1.5 ml reaction tube. Add 50 μl Elution 
Buffer, incubate for 1 min at room temperature. Centrifuge for 1 min at 8000 x g to 
collect the eluated RNA. 
21) The microcentrifuge tibe now contains the eluted RNA. Either use 10 μl of the 
eluted RNA directly in RT-PCR or store the eluted RNA at - 80°C for later 
analysis. Before photometrical determination of RNA concentration, centrifuge the 
eluate for 3 mins at maximum speed and transfer supernatant to a fresh 1.5 ml 
reaction tube without disturbing glass fibers at the bottom of the original tube. 
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APPENDIX F.   RT-PCR used for cell lines 
 
1. Dosage of RNA: 
 Refer to the quantity of RNA that was calculated by the Nanodrop. This dosage is 
given in ng/μl.  
 This dosage gives you the volume of RNA to use for doing a RT-PCR, meaning 2 μg 
and the volume of water that must be added to have a total volume of 11 μl. 
 For example, if you have 945.92 ng/μl of RNA in your isolation, for 2000ng you will 
have 2.11 μl of RNA.  You must then add 8.89 μl of miliQ water to your sample to 
have a total of 11 μl. 
 
2. RT-PCR: 
 Use PCR RNAse free tubes 
 X μl of RNA (see Dosage instructions above) 
 Y μl of miliQ water (as described above for total of 11 μl) 
 1 μl of Random Hexamer 
 Thus you have a total of 12 μl 
 
 Place in PCR instrument with the following program: 
o 5 minutes at 70°C 
o Pause at 4°C 
 
 Then add 8 μl of the following mix to each tube: 
o 5x reaction buffer : 4  μl 
o Ribonuclease inhibitor : 1 μl 
o dNTPs 10mM : 2 μl 
o revertaid H minus : 1 μl 
 
 Place back in PCR instrument with the following program: 
o 1 hour at 42°C 
o 10 minutes at 70°C 
o Pause at 4°C 
 
You now have cDNA that can be used for Q-PCR  
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APPENDIX G.  RT-PCR used for Fresh and FFPE tissue 
    High Capacity cDNA RT Kit (ABI) 
 
 
1. Thaw the RNA and all kit components 
 
2. Prepare the master mix of the reverse transcription according to the following table: 
 
Components 2 μg 5 μg 
10X Reverse Transcript Buffer 2 μl 5 μl 
10X Random Primer or Gene Specific Primer*** 2 μl 5 μl 
25X dNTPs 0.8 μl 2 μl 
Multiscribe Reverse Transcriptase Enzyme (50U/μl) 1 μl 2.5 μl 
Nuclease free H2O 4.2 μl 10.5 μl 
RNA diluted in H2O 10 μl 25 μl 
TOTAL 20 μl 50 μl 
*** Gene Specific Primer = 1 μl of  each of the 25 genes + 1 μl of each of the 3 housekeeping 
genes pooled together and mixed using ABI Taqman Assays (have 3’+ 5’ oligo + 
fluorescence). Thus, when using this protocol use 2 μl of this mix instead of the Random 
Hexamer 
 
3. Place in PCR instrument with the following program 
o 10 mins at 25°C 
o 2 hours at 37°C 
o Pause at 4°C 
 
4. Conserve cDNA at 4°C if used within the next 24 hours or at -20°C if using a later date.  
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APPENDIX H.   QPCR ABI Protocol 
 
 In each well pipet: 
o 5 μl – 2X TaqMan FastMix 
o 0.5 μl – ABI TaqMan Assay (20X) 
o 1.5 μl – cDNA 
o 3 μl – H2O 
 
 Then the plate is run by the 7900HT RT-QPCR machine 
 
 
APPENDIX I.   Analysis of Results from Q-PCR 
 
Definitions of the terms of the results 
 
Ct = Cycle Threshold 
Value at which point the PCR curve crosses the threshold. A qPCR has approximately 40 
cycles. The higher the Ct (30-35), the less present is the detected mRNA, because it requires 
more PCR cycles to detect the fluorescent amplification. If the Ct is small (10-15), the gene is 
strongly expressed. The housekeeping genes often have a smaller Ct then the other genes. 
 
Delta Ct = Ct gene – Ct housekeeping gene 
 
Delta Delta Ct = Delta Ct sample1 – Delta Ct calibrator 
 
Delta Ct SD = Standard Deviation 
The Standard deviation is calculated by the software. This error reflects the quality of the 
triplicates technique for the gene being tested and the housekeeping gene for the same sample. 
For the value to be considered valid, the standard deviation should be under 0.25. If the 
standard deviation is higher than 0.25, the RQ value is considered not reliable. 
 
RQ = Relative Quantification = 2 -∆∆Ct  
This is the fold change. The calibrator is fixed at a value of 1. The other samples have a value 
with regards to the calibrator. A value of 10 indicates that the expression of the gene is 10X 
more than the calibrator. A value of 0.1 indicates that the expression of the gene is 10X less 
than the calibrator. An RQ greater than 2 or less than 0.5 is considered significant. 
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APPENDIX J.    Q-PCR on LDA Protocol 
 
 
1. Prepare a master mix for each cDNA being tested 
 
For Duplicates prepare the following according to this guide : 
Components 
48 genes on 96 well plate 
20 predicitve genes (duplicates) 
4 housekeeping genes (duplicates) 
2X TaqMan mix 100 μl 
cDNA (25ng/ μl) 10 μl 
MilliQ H2O 90 μl 
Total 200 μl 
 
2. Distribute (2X for 48 genes) 100 μl of the mix to each port site 
3. Centrifuge 2 x at 1200 rpm for 1 minute 
4. Seal the plate with the ABI plate sealer 
5. Cut the excess seal around the plate with scissors 
6. Run the plate on the 7900HT Real-Time qPCR or conserve at 4°C for a maximum of 48 
hours 
7. PCR program: 
 95°C for 10 minutes 
 95°C for 15 seconds (45 cycles) 
 60°C for 1 minute 
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APPENDIX K.  Consent Form and Research Protocol 
 
 
FORMULAIRE D’INFORMATION ET DE CONSENTEMENT ÉCLAIRÉ DESTINÉ 
À LA PATIENTE 
Recherche sur échantillons biologiques et de données cliniques et biologiques sur le cancer du 
sein 
Chercheurs Principaux : 
Dre. Sylvie Mader, Ph.D.  Institut de Recherche de l’Immunologie et Cancérologie de 
l’Université de Montréal. 
Dr. André Robidoux, M.D. Chirurgien oncologue, Département de Chirurgie Oncologique,  
Hôtel Dieu de Montréal, CHUM 
____________________________________________________________________________ 
Préambule : 
Vous êtes invitée à contribuer à cette étude parce que vous avez été opérée au sein dans le 
contexte d’un protocole de recherche du NSABP.  Lors de votre consentement à ce protocole 
vous avez autorisé le laboratoire de pathologie de l’hôpital Hôtel-Dieu de Montréal du Centre 
Hospitalier de l’Université de Montréal à conserver vos échantillons biologiques de vos tissus 
mammaires en bloc de paraffine après votre chirurgie dans le but des recherches du NSABP.  
On vous demande si vous souhaitez participer à cette nouvelle recherche où on utilisera ces 
mêmes échantillons biologiques afin de répondre à nos nouvelles questions de recherche.     
 
Également, les chercheurs peuvent avoir besoin de renseignements vous concernant.  À cet 
effet, les chercheurs autorisés par ce projet de recherche consulteront votre dossier médical 
pour obtenir les informations indispensables pour leur permettre d’analyser les résultats de ces 
recherches.  Elles incluent votre âge, votre sexe, votre groupe ethnique, votre diagnostic, votre 
état de santé actuel, l’existence d’antécédents médicaux personnels et familiaux, les 
traitements que vous avez reçus et comment vous y avez répondu.  Ces informations seront 
informatisées en respectant les règles de confidentialité telles que prévue par la législation 
provinciale et fédérale. 
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1. DÉFINITIONS 
 
En recherche biomédical, est appelé échantillon biologique tout organe, tissu ou autre 
substance biologique (par exemple le sang, urine, etc.) prélevé sur une personne.  Le sérum 
représente la partie liquide du sang.  Les lignées cellulaires sont des cellules provenant d’un 
échantillon biologique qui ont été traitées de façon à être capables de se multiplier en 
laboratoire.   
 
Les gènes sont des molécules qui renferment toutes les informations génétiques transmissibles 
permettant un bon fonctionnement des cellules de notre corps, ainsi que les informations 
permettant à ces cellules de se défendre contre les agressions diverses dont notre corps fait 
l’objet.  Nos gènes fournissent aussi l’information qui détermine nos caractères héréditaires, 
tels que la couleur de nos yeux ou notre groupe sanguin.  Cette information génétique est 
portée par l’ADN.  Il correspond à des phrases écrites avec un alphabet de 4 lettres, le code 
génétique, qui va être traduit en protéine par l’intermédiaire d’un messager (ARN).  Ces 
protéines qui constituent notre organisme sont indispensables au bon fonctionnement de 
l’individu.  Une anomalie, même d’une seule lettre dans la phrase, peut favoriser l’apparition 
de cancers.  L’identification des ces anomalies permettra de mieux comprendre les 
mécanismes d’apparition de ces cancers. 
 
 
2. JUSTIFICATION DU PROJET 
 
Le cancer du sein est un problème de santé majeure pour les femmes.  Dans 5-10% des cas, il 
peut exister une prédisposition familiale à développer un cancer.  Des chercheurs travaillent 
dans ces domaines, à la recherche des causes de cette maladie qu’elle soit ou non d’origine 
familiale, ainsi qu’à la recherche de nouveaux traitements.  Pour que ces recherches puissent 
se poursuivre, les chercheurs ont besoin d’échantillons biologiques provenant autant d’organes 
ou de tissus sains que d’organes ou de tissus présentant des problèmes bénins ou malins.  De 
plus, les chercheurs peuvent avoir besoin que les cellules, obtenues à partir de votre 
échantillon biologique, soient mises en culture (formations de lignées cellulaires) de façon à 
disposer de suffisamment de matériel biologique pour réaliser les recherches.  Dans certains 
cas, en particulier dans le cas de cellules normales ou proche de la normale, elles doivent être 
traitées pour être capable de se multiplier.      
 
3. OBJECTIF DU PROJET 
Les 2/3 des cancers du sein sont positifs pour le récepteur des œstrogènes (ER) et sont 
stimulés par les œstrogènes. Un traitement de Tamoxifen (anti-œstrogène) peut réduire le taux 
de rechute des cancers ER positive ainsi qu’augmenter la survie des femmes atteinte de ces 
cancers.  Toutefois cette thérapie n’est pas efficace dans tous les cancers du sein ER-positives.  
L’hormonothérapie va bénéficier à environ 60-70% des cancers ER-positives. Nous avons 
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identifié 20 gènes qui  peuvent prédire la réponse au Tamoxifen pour nous dire quelles 
femmes en bénéficient le plus.  Nous voulons valider ces 20 gènes sur des tumeurs de cancer 
du sein traités ou non avec du Tamoxifen.  Par la suite nous voulons développer un outil qui 
pourrait prédire la réponse au Tamoxifen.  En faisant ceci on pourrait savoir à qui ce 
traitement est bénéfique et à qui le traitement est futile. 
 
4. BÉNÉFICES 
 
Il se peut que vous retiriez un bénéfice personnel de votre participation à ce projet de 
recherche, mais on ne peut vous l’assurer.  Par ailleurs, les résultats obtenus contribueront à 
l’avancement des connaissances dans ce domaine. 
 
 
5. RISQUES 
 
Puisque vous étiez déjà opéré dans le passé et on a déjà vos tissus au laboratoire, il n’y a aucun 
risque supplémentaire pour votre santé si vous participez à cette étude.  Dans le cas présent, 
nous allons prendre des mesures strictes en matière de confidentialité et de sécurité des 
données qui vont être contenues dans notre recherche ainsi qu’en matière de respect de la vie 
privée.  Nous nous engageons à ne divulguer aucune information, ni à votre famille, ni à des 
assureurs ou employeurs, sans votre consentement écrit. 
 
 
6. CONFIDENTIALITÉ 
 
Durant votre participation à ce projet de recherche visant d’utiliser du matériel biologique, le 
chercheur responsable ainsi que son personnel recueilleront certains renseignements vous 
concernant de votre dossier médical. 
 
Ces renseignements comprennent des informations concernant votre âge, votre sexe, votre 
origine ethnique, votre diagnostic, votre état de santé passé et présent, votre histoire familiale 
ainsi que des résultats de tous les tests, examens et procédures que vous auriez déjà passé. 
 
Seuls les renseignements nécessaires pour répondre aux objectifs scientifiques de ce projet 
seront recueillis.  Les chercheurs utiliseront les données et les échantillons biologiques dans le 
but de répondre à ces objectifs scientifiques. 
 
Tous les renseignements et les échantillons biologiques recueillis au cours de ce projet 
demeureront strictement confidentiels dans les limites prévues par la loi.  Afin de préserver 
votre identité ainsi que la confidentialité des renseignements et des échantillons, un numéro de 
code leur sera attribué.  La clé du code reliant votre nom aux renseignements et aux 
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échantillons sera conservé par le Dr. André Robidoux.  Votre nom et vos coordonnées ne 
feront pas partie des informations versées dans la banque de données et de matériels 
biologiques.   
 
Vos échantillons de cancer du sein en bloc de paraffine sont conservée de façon indéfini tel 
que déjà prévu avec le NSABP, lors de votre consentement au protocole du NSABP. 
 
Les données pourront être publiées dans des revues spécialisées ou faire l’objet de discussions 
scientifiques, mais il ne sera pas possible de vous identifier. 
 
À des fins de surveillance et de contrôle, la banque de données et de matériels biologiques 
pourra être consultée par une personne mandatée par le Comité d’éthique de la recherche de 
l’établissement, par une personne mandatée par des organismes publics autorisés.  Toutes ces 
personnes et ces organismes adhèrent à une politique de confidentialité. 
 
Vous avez le droit de consulter la banque de données et de matériels biologiques pour vérifier 
les renseignements recueillis vous concernant, et les faire rectifier au besoin, et ce, aussi 
longtemps que le chercheur responsable du projet ou l’établissement détiennent ces 
informations.          
 
 
7. COMMERCIALISATION 
 
Votre échantillon biologique ne pourra être vendu.  Par conséquent, il sera utilisé uniquement 
à des fins de recherche.  L’analyse de celui-ci pourra contribuer à la création de produits 
commerciaux dont vous ne pourrez retirer aucun avantage financier.  Ces avantages financiers 
seront partagés entre le chercheur et l’Université de Montréal selon un protocole d’entente 
convenu par les deux parties. 
 
 
8. INFORMATIONS SUR LES RÉSULTATS 
 
La recherche requiert beaucoup de temps.  C’est pourquoi nous ne pourrons vous donner les 
résultats de ces recherches dans l’immédiat. 
 
Toutefois, dans le cas où les travaux de recherche aboutiraient à des résultats scientifiquement 
validés, pertinents à votre condition et à un éventuel traitement, si vous le désirez, vous serez 
contactée par l’intermédiaire d’un professionnel de la santé.  Si vous souhaitez connaître votre 
statut personnel regardant cette information, le résultat ne pourra vous être donné qu’après 
avoir été confirmé par un nouveau test biologique fait dans un cadre clinique. 
 
Si l’information obtenue peut avoir un impact sur la santé d’autres membres de votre famille, 
et dans l’éventualité de votre décès ou d’une autre cause vous rendant incapable de vous 
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déplacer pour connaître ce résultat, vous pouvez autoriser un professionnel de la santé de 
contacter une ou plusieurs personnes de votre famille que vous désignerez. 
 
 
9. LIBERTÉ DE PARTICIPATION ET DROIT DE RETRAIT 
 
Votre contribution à cette recherche est tout à fait volontaire.  Vous êtes donc libre d’accepter 
ou de refuser d’y contribuer sans subir de préjudice sur vos soins actuels ou futurs. 
 
Vous pouvez changer d’avis à tout moment.  Si vous ne souhaitez plus que votre échantillon 
biologique soit utilisé à des fins de recherche, vous n’avez qu’à contacter le responsable du 
projet de recherche. 
 
Votre échantillon biologique sera alors garder comme tel dans la banque du NSABP et ne sera 
plus utilisé. 
 
Cependant, tous les résultats qui auront été obtenus avec votre échantillon avant la date de 
désistement seront conservés.  Par la suite, vous ne serez pas recontactée et ne pourrez pas être 
informée si la recherche aboutit à des résultats scientifiquement validés.  Si vous vous retirez 
du projet, à ce moment là, votre dossier médical ne sera plus consulté à des fins de recherche. 
 
10. PROBLÈMES OU QUESTIONS 
 
Si vous avez des questions concernant la constitution de ce projet de recherche, veuillez 
contacter le responsable du projet, André Robidoux 514-890-8000, poste 15535. 
 
Pour toute question concernant vos droits en tant que sujet participant à ce projet de recherche 
vous pouvez communiquer avec la commissaire adjointe à la qualité des services de 
l’Hôpital Hôtel-Dieu de Montréal : Michèle Morin 514-890-8000, poste 12761. 
 
 
11. SURVEILLANCE ÉTHIQUE 
 
Le comité d’éthique de la recherche du CHUM a approuvé ce projet de recherche et en assure 
le suivi.  De plus, il approuvera au préalable toute révision et toute modification apportée au 
formulaire d’information et de consentement et au protocole de recherche. 
 
12. CONSENTEMENT 
 
J’ai lu le présent formulaire de consentement intitulé ‘’Recherche sur échantillons biologiques 
et de données cliniques et biologiques sur le cancer du sein’’.  J’ai eu l’occasion de poser 
toutes mes questions au sujet du projet de recherche, et les réponses obtenues ont été 
satisfaisantes. 
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Je comprends que ma participation au projet se fait sur une base entièrement volontaire, e que 
je demeure libre de me retirer du projet à tout moment et sans préjudice.  Il est entendu que, 
quelle que soit ma décision, cela n’affectera en aucune façon les soins que je devrais recevoir.  
En signant le présent formulaire, je ne renonce à aucun des mes droits légaux ni ne libère les 
chercheurs, l’hôpital de leur responsabilité civile et professionnelle.   
 
Je recevrai une copie signée et datée de se formulaire d’information et de consentement. 
 
En conséquence, je consens aux points suivants : 
 
A) Étude sur le cancer su sein : 
 
 J’accepte qu’une partie de mon matériel biologique qui a été prélevé dans le passé 
pour le protocole du NSABP puisse être utilisé à des fins de recherches, et 
j’autorise l’accessibilité à mon dossier médical afin de fournir les informations 
nécessaires à l’utilisation de cet échantillon. 
 
(  ) OUI      (  ) NON 
 
B) Choix d’être recontactée : 
 
 J’autorise le responsable du projet ou son délégué à me contacter par téléphone si 
des informations complémentaires étaient nécessaires. 
 
(   ) OUI    Téléphone : ______________    (    ) NON 
 
 Je désire être recontactée si la recherche sur le cancer du sein aboutit à des résultats 
scientifiquement validés. 
 
(   ) OUI    Téléphone : ______________    (    ) NON 
 
 
En faisant le choix d’être recontactée dans le cas où la recherche aboutirait à des résultats 
scientifiquement validés, je m’engage à tenir l’équipe de recherche informée de mes 
coordonnées. 
En cas de non disponibilité, j’autorise le responsable du projet de recherche ou son délégué à 
contacter : 
_______________________ lien de parenté :____________________________ 
No de téléphone : _________________________________ 
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Après avoir indiqué vos choix, veuillez inscrire votre nom et votre signature ci-dessous. 
   
_____________________     ________________________    __________________ 
  
Nom de la participante              Signature de la participante          Date 
 
_____________________   _________________________   ___________________ 
Nom du témoin              Signature du témoin    Date 
 
Je certifie qu’on a expliqué au signataire intéressé les termes du présent formulaire, qu’on a 
répondu aux questions qu’elle à posées à cet égard, qu’on lui a clairement indiqué qu’il reste à 
tout moment libre de mettre un terme à sa participation au projet de recherche et décrite ci-
dessus.  Une copie signée du présent formulaire de consentement lui a été remise. 
   
_____________________   _________________________   ___________________ 
Nom du responsable          Signature du responsable  Date 
du projet de recherche          du projet de recherche 
   
 
_____________________   _________________________   ___________________ 
  
Nom de la personne qui       Signature de la personne qui Date 
obtient le consentement       obtient le consentement         
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APPENDIX L.   Approval of Scientific Committee 
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APPENDIX M.   Approval Ethics Committee 
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